

Children's Hospital Medical Center and Affiliates

Title 2 U.S. Code of Federal Regulations
Part 200 (Uniform Guidance) Reports for
the Year Ended June 30, 2025

Children’s Hospital Medical Center and Affiliates

Table of Contents

	<u>Page(s)</u>
INDEPENDENT AUDITOR’S REPORT	1–2
CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2025 AND 2024:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	4–5
Consolidated Statements of Cash Flows	6–7
Notes to Financial Statements	8–33
SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2025	34–48
NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2025	49
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH <i>GOVERNMENT AUDITING STANDARDS</i>	50–51
REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL REQUIRED BY THE UNIFORM GUIDANCE	52–54
SCHEDULE OF FINDINGS AND QUESTIONED COSTS	55–56

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees
Children's Hospital Medical Center and Affiliates:
Cincinnati, Ohio

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the consolidated balance sheets as of June 30, 2025 and 2024, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2025 on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

Deloitte + Touche LLP

September 30, 2025

Children's Hospital Medical Center and Affiliates

Consolidated Balance Sheets
June 30, 2025 and 2024 (dollars in thousands)

	<u>2025</u>	<u>2024</u>
CURRENT ASSETS:		
Cash and cash equivalents	\$ 258,518	\$ 189,507
Marketable securities	1,315,026	1,335,526
Total cash, cash equivalents and marketable securities	<u>1,573,544</u>	<u>1,525,033</u>
Patient receivables, net	723,994	704,875
Other receivables	236,797	236,163
Inventories and prepaid expenses	73,299	93,336
Total current assets	<u>2,607,634</u>	<u>2,559,407</u>
ASSETS LIMITED AS TO USE - Funds in trust	20,512	40,186
PROPERTY AND EQUIPMENT, net of accumulated depreciation	1,812,174	1,650,130
GOODWILL	4,721	5,579
OPERATING LEASE RIGHT-OF-USE ASSETS	19,545	20,696
PENSION BENEFIT ASSET	102,918	132,504
OTHER LONG-TERM ASSETS	152,107	126,626
INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS	6,039,512	5,527,851
Total assets	<u>\$ 10,759,123</u>	<u>\$ 10,062,979</u>
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	\$ 577,723	\$ 532,445
Current portion of long-term debt and lease obligations	20,281	20,063
Commercial paper	-	100,000
Bonds payable subject to remarketing, net	61,542	70,023
Total current liabilities	<u>659,546</u>	<u>722,531</u>
SELF-INSURANCE RESERVES	14,870	17,443
LONG-TERM DEBT:		
Tax-exempt bonds payable	287,512	301,036
Taxable bonds payable	596,867	596,637
Loans payable	52,990	-
Finance lease obligations	34,378	41,202
Operating lease obligations	17,241	18,484
OTHER LONG-TERM LIABILITIES	16,128	15,283
Total liabilities	<u>1,679,532</u>	<u>1,712,616</u>
COMMITMENTS AND CONTINGENCIES (Note 11)	-	-
NET ASSETS:		
Without donor restrictions	2,798,816	2,602,373
With donor restrictions	6,280,775	5,747,990
Total net assets	<u>9,079,591</u>	<u>8,350,363</u>
Total liabilities and net assets	<u>\$ 10,759,123</u>	<u>\$ 10,062,979</u>

See accompanying notes to Consolidated Financial Statements.

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets
For the Years Ended June 30, 2025 and 2024 (dollars in thousands)

	<u>2025</u>	<u>2024</u>
OPERATING REVENUES, GAINS AND OTHER SUPPORT:		
Net patient service revenue	\$ 2,876,836	\$ 2,765,941
Net assets released from restriction used for operations-		
Grant revenue	243,844	254,163
Other restricted net assets used to support operations	174,013	160,880
Other revenue	206,102	196,719
Total operating revenues, gains and other support	<u>3,500,795</u>	<u>3,377,703</u>
OPERATING EXPENSES:		
Salaries	1,781,646	1,668,703
Employee benefits	450,513	431,024
Supplies, drugs and other	626,849	599,215
Purchased services	384,848	376,866
Depreciation and amortization	158,916	152,764
Utilities	25,393	22,028
Interest	30,416	32,860
Total operating expenses	<u>3,458,581</u>	<u>3,283,460</u>
Operating income	<u>42,214</u>	<u>94,243</u>
NONOPERATING GAINS:		
Net investment return	126,977	127,935
Net benefit gain other than service cost	39,381	37,863
Net nonoperating gains	<u>166,358</u>	<u>165,798</u>
Revenue and gains in excess of expenses	208,572	260,041
OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS:		
Receipts and receipts due from supporting organizations	2,637	53,292
Net assets released from restrictions used for purchase of property and equipment	7,435	21,585
Consolidation of sole member entity	-	4,017
Transfers to supporting organizations	(20)	(4,185)
Pension and post-retirement health liability adjustment	(22,181)	(43,286)
Increase in net assets without donor restrictions	<u>\$ 196,443</u>	<u>\$ 291,464</u>

(Continued on next page)

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets
For the Years Ended June 30, 2025 and 2024 (dollars in thousands)

	<u>2025</u>	<u>2024</u>
NET ASSETS WITH DONOR RESTRICTIONS:		
Contributions and investment income-		
Grant receipts	\$ 243,617	\$ 255,744
Gifts and contributions of financial assets and other income	235,669	176,011
	<u>479,286</u>	<u>431,755</u>
Net assets released from restriction-		
Grant expenditures	(243,844)	(254,163)
Net assets with donor restrictions used to support operations	(174,013)	(160,880)
Net assets with donor restrictions used for purchase of property and equipment	(7,435)	(21,585)
	<u>(425,292)</u>	<u>(436,628)</u>
Gain in interest in net assets of supporting organizations	511,661	658,703
Net assets transferred to supporting organizations	(32,870)	-
Consolidation of sole member entity	-	2,187
	<u>532,785</u>	<u>656,017</u>
Increase in net assets with donor restrictions		
	<u>532,785</u>	<u>656,017</u>
INCREASE IN NET ASSETS	729,228	947,481
NET ASSETS, beginning of year	<u>8,350,363</u>	<u>7,402,882</u>
NET ASSETS, end of year	<u>\$ 9,079,591</u>	<u>\$ 8,350,363</u>

See accompanying notes to Consolidated Financial Statements.

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Cash Flows

For the Years Ended June 30, 2025 and 2024 (dollars in thousands)

	<u>2025</u>	<u>2024</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	\$ 729,228	\$ 947,481
Adjustments to reconcile increase in net assets to net cash provided by operating activities-		
Depreciation and amortization	159,223	151,914
Loss on disposal of property and equipment	483	752
Proceeds from sale of donated securities	694	466
Receipts from supporting organizations	(52,637)	(3,292)
Contributions of financial assets to supporting organizations	20	4,185
Contributions of financial assets restricted for purchase of property and equipment	(7,435)	(21,585)
Gain in interest in net assets of supporting organizations	(479,704)	(658,703)
Unrealized and realized gains on marketable securities, net	(90,682)	(84,076)
Loss on interest rate swap	1,998	1,013
Increase in receivables	(19,753)	(187,574)
Increase in inventories and prepaid expenses and other assets	(7,442)	(41,215)
Decrease in pension benefit asset	29,586	53,494
Increase in accounts payable and accrued expenses, net	51,079	33,818
Decrease in operating lease obligations	(2,992)	(3,062)
Decrease in self-insurance reserves and other long-term liabilities	(728)	(4,889)
Net cash provided by operating activities	<u>310,938</u>	<u>188,727</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Expenditures for property and equipment	(327,385)	(239,464)
Purchases of marketable securities	(859,417)	(1,079,864)
Sales and maturities of marketable securities	969,943	1,126,586
Cash withdrawn from funds in trust	-	3,620
Cash invested in funds in trust	-	(8,673)
Net cash used in investing activities	<u>(216,859)</u>	<u>(197,795)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Issuance of bonds and loans payable	52,990	66,155
Repayment of bonds, loans payable, and finance lease obligations	(25,827)	(90,002)
Repayment of commercial paper	(100,000)	-
Contributions restricted for purchase of property and equipment	7,435	21,585
Receipts from supporting organizations	52,637	3,292
Contributions to supporting organizations	(20)	(4,185)
Net cash used in financing activities	<u>(12,785)</u>	<u>(3,155)</u>
Net increase (decrease) in cash, cash equivalents, and restricted cash	81,294	(12,223)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, beginning of year	<u>197,736</u>	<u>209,959</u>
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, end of year	<u>\$ 279,030</u>	<u>\$ 197,736</u>

(Continued on next page)

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Cash Flows

For the Years Ended June 30, 2025 and 2024 (dollars in thousands)

	<u>2025</u>	<u>2024</u>
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:		
Transfer of endowment funds to supporting organization	\$ 32,870	\$ -
Capital expenditures in accounts payable and accrued expenses	29,608	36,409
Acquisition of property through operating leases	2,112	7,897

See accompanying notes to Consolidated Financial Statements.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

(1) Accounting Policies –

- (a) Basis of Consolidation – Children's Hospital Medical Center (Cincinnati Children's), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), HealthVine LLC (HealthVine), Every Child Succeeds (ECS), Cincinnati Children's Global (CCG), and other investment holding entities are included in the accompanying Consolidated Financial Statements and are collectively referred to as Cincinnati Children's. The previously named entities are all wholly own subsidiaries of Cincinnati Children's whose intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, education, and research. River City is a captive insurance company. CHSN's purpose is to manage primary care practices in a community setting. HealthVine supports the population health and care coordination initiatives of Cincinnati Children's. ECS is a not-for-profit organization designed to optimize child development for first-time, at-risk mothers. CCG supports the advancement of pediatric healthcare internationally.

Effective August 2023, Cincinnati Children's became the sole member of ECS with no consideration paid. Consequently, Cincinnati Children's assumed the fair value of assets of \$7,920 and the fair value of associated liabilities of \$1,716 resulting in an increase in Net assets without donor restrictions of \$4,017 and an increase in Net assets with donor restrictions of \$2,187.

- (b) Supporting Organizations – The Children's Hospital (TCH) and Convalescent Hospital Fund for Children (CHFC) are both Ohio not-for-profit corporations that provide financial support to Cincinnati Children's. The TCH and CHFC purpose clauses both specify the support of Cincinnati Children's as the organization's sole purpose. Additionally, certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children's. As such, the assets of TCH and CHFC are recorded in Cincinnati Children's Consolidated Financial Statements as Interest in net assets of supporting organizations and as Net assets with donor restrictions. Changes in the fair value of Interest in net assets of supporting organizations are recorded as a Gain in interest in net assets of supporting organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

The majority of receipts are from TCH and CHFC donor-restricted endowment funds or are other receipts that are designated by the supporting organizations' Boards of Trustees for specific operating purposes. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon spending, such funds are reflected in Other restricted net assets used to support operations in the Consolidated Statements of Operations and Changes in Net Assets.

Other receipts from TCH are designated by the supporting organization's Board of Trustees to provide general support. The receipts are reflected in Receipts and receipts due from supporting organizations without donor restriction in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

- (c) Support Received from Supporting Organizations – TCH and CHFC provide annual support to Cincinnati Children's through transfers of dividend and interest earnings on investments, net of investment management fees, administrative expenses, and donor-required income reinvestments.

The supporting organizations' respective Boards of Trustees may also make certain pledges of principal without donor restriction in support of key projects or initiatives at Cincinnati Children's. In

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

January 2020, CHFC’s Board of Trustees made a gift in the amount of \$36,000 to support the construction of a new facility at the College Hill Campus and programmatic support of Cincinnati Children’s *Pursuing our Potential in Mental Health* initiative. The agreement has certain criteria that represent donor-imposed conditions that must be overcome before Cincinnati Children’s is entitled to the assets promised. Contributions of \$7,750 and \$10,000 were made for the years ended June 30, 2025 and June 30, 2024, respectively. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions and in Net assets released from restrictions used for purchase of property and equipment in the Consolidated Statements of Operations and Changes in Net Assets.

During fiscal year 2024, TCH’s Board of Trustees approved a request from Cincinnati Children’s for \$50,000. This represents a return of funds previously transferred to TCH from Cincinnati Children’s Net assets without donor restrictions. The commitment is intended to support research capital projects. At June 30, 2024, the transaction was recorded as an Other receivable and as a Receipt due from supporting organizations without donor restrictions. These funds were subsequently received in fiscal year 2025. During fiscal year 2025, TCH’s Board of Trustees approved an additional request from Cincinnati Children’s for \$50,000. This represents a payment of undistributed income from TCH to Cincinnati Children’s to support research initiatives. At June 30, 2025, the transaction was recorded as Gifts and contributions of financial assets and other income.

The following table details transfers between Cincinnati Children’s and Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets:

	<u>2025</u>	<u>2024</u>
Transfers of net assets with donor restrictions included in		
Gifts and contributions of financial assets and other income:		
Cincinnati Children’s from TCH	\$ 183,934	\$ 125,215
Cincinnati Children’s from CHFC	11,712	16,360
Cincinnati Children’s to TCH (1)	(32,870)	-
Total	<u>\$ 162,776</u>	<u>\$ 141,575</u>
Transfers of net assets without donor restrictions included in		
Receipts from (Transfers to) supporting organizations:		
Cincinnati Children’s from TCH	\$ 2,637	\$ 3,292
Cincinnati Children’s due from TCH	-	50,000
Cincinnati Children’s to TCH (2)	(20)	(4,185)
Total	<u>\$ 2,617</u>	<u>\$ 49,107</u>

- (1) In July 2024, Cincinnati Children’s transferred \$32,870 of Endowment funds held in perpetual trust to The Children’s Hospital. The purpose of this transfer is to align all permanently restricted gifts within the Endowment Entity.
- (2) The purpose of this transfer is to establish funds designated to support divisional activities and strategic priorities.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

- (d) Revenue Recognition – The following revenue streams are subject to the revenue recognition guidance in Accounting Standards Codification No. 606 (ASC 606) “Revenue from Contracts with Customers”:

	<u>2025</u>	<u>2024</u>
Net patient service revenue	\$ 2,876,836	\$ 2,765,941
Other revenue	206,102	196,719
	<u>\$ 3,082,938</u>	<u>\$ 2,962,660</u>

Net Patient Service Revenue

Cincinnati Children’s net patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients. As patients simultaneously receive and consume the benefits of health care provided by Cincinnati Children’s, the performance obligations meet the criteria to be satisfied over time. Net patient service revenue is recorded as services are provided. Payment for such services is due between thirty to forty-five days from payer receipt of claim. Consideration for patient service revenue is variable. Agreements with payers typically provide for payments at amounts less than established charges.

Cincinnati Children’s has agreements with Ohio Medicaid managed care companies in which performance obligations are to stand-ready to provide care for approximately 130,000 children. The performance obligations are satisfied over time. Cincinnati Children’s is reimbursed under a variable capitation methodology in alignment with contracts in place. Under delegation agreements, Cincinnati Children’s receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers. The amount of net patient service revenue recorded under this arrangement in fiscal year 2025 and 2024 was \$131,607 and \$98,311, respectively.

Laws and regulations concerning government programs, including Medicaid and Medicare, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from related programs. There can be no assurance that regulatory authorities will not challenge Cincinnati Children’s compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Cincinnati Children’s. In addition, the contracts Cincinnati Children’s has with third party payers also provide for retroactive audit and review of claims. At June 30, 2025, Cincinnati Children’s has settled all Medicaid cost reports through 2020 and all Medicare cost reports through 2022.

Settlements with third party payers for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are based on the terms of the payment agreement with the payer, correspondence from the payer, and Cincinnati Children’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Estimated settlements are adjusted in future periods as adjustments become known based on new information or as years are settled and no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in transaction price were not material in fiscal years 2025 and 2024.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Generally, patients who are covered by third party payers are responsible for related deductibles and coinsurance, which vary in amount. Cincinnati Children's also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. Cincinnati Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by established contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change.

Consistent with Cincinnati Children's mission, care is provided to patients regardless of their ability to pay. Therefore, Cincinnati Children's has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances. The implicit price concessions included in estimating the transaction price represent the difference between the amounts billed to patients and the amounts Cincinnati Children's expects to collect based on its collection history with those patients.

Patients who meet Cincinnati Children's criteria for charity care are provided care without charge or at amounts less than established rates. Amounts determined to qualify as charity care are not reported as net patient service revenue.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, Cincinnati Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the fiscal year. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the fiscal year. The performance obligations for these contracts are generally completed when patients are discharged, which generally occurs shortly after the end of the fiscal year.

In both fiscal years 2025 and 2024, substantially all net patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements). Cincinnati Children's classifies its patients by payer. The following table disaggregates Cincinnati Children's net patient service revenue by payer categories for the fiscal year ended June 30, 2025 and 2024:

	2025		2024	
Managed care and commercial insurers	63%	\$ 1,811,327	63%	\$ 1,743,742
Government (HMO and third party)	30%	872,830	30%	821,469
International	4%	103,287	4%	116,154
Specialty contracts ¹	2%	69,434	2%	55,898
Self-pay	1%	19,958	1%	28,678
		<u>\$ 2,876,836</u>		<u>\$ 2,765,941</u>

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

The following details the percentage of accounts receivable by payer category as of June 30, 2025 and 2024:

	<u>2025</u>	<u>2024</u>
Managed care and commercial insurers	62%	52%
Government (HMO and third party)	21%	25%
International	7%	17%
Specialty contracts ¹	3%	3%
Self-pay	7%	3%

¹ Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

Other Revenue

Cincinnati Children’s other revenue generally relates to contracts with external organizations in which the performance obligations are to provide research services or other various fee-for-service arrangements outside the scope of healthcare services.

Revenue from industry contracts and certain government contracts is earned based on performance obligations to provide research services to the external organizations. License and royalty revenue relates to contracts with other organizations in which our performance obligations are to provide intellectual property to the organization. Revenue is also earned for various other contracted fee-for-service arrangements where services are performed for external organizations outside the scope of healthcare services for Cincinnati Children’s patients. Performance obligations for industry and government contracts, license and royalty contracts, and various other fee-for-service arrangements are satisfied over time. Consideration is fixed based on contracted price, and there is no significant variable consideration related to these agreements.

A contract liability exists when an entity has an obligation to transfer goods or services to a customer. Cincinnati Children’s has contract liabilities of \$69,638 and \$67,954 recorded within Accounts payable and accrued expenses for the years ended June 30, 2025 and 2024, respectively.

- (e) Graduate Medical Education – Cincinnati Children’s receives Federal graduate medical education funding. Other revenue of \$12,114 and \$12,532 was recognized for the years ended June 30, 2025 and 2024, respectively.
- (f) Tax Exempt Status – Cincinnati Children’s, CHSN and ECS are exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as organizations described in Section 501(c)(3). HealthVine and CCG are single-member LLC wholly owned by Cincinnati Children’s treated as a disregarded entity of Cincinnati Children’s for income tax purposes. River City is a captive insurance corporation wholly owned by Cincinnati Children’s. Cincinnati Children’s, CHSN, ECS, HealthVine, CCG and River City are generally not subject to federal or state income tax obligations. Other investment holding entities’ income is taxable to Cincinnati Children’s. The income tax provisions recorded in the accompanying Consolidated Financial Statements are immaterial for the years ended June 30, 2025 and 2024.

Cincinnati Children’s accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 “Income Taxes”. It is Cincinnati Children’s policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal years 2025 and 2024. Cincinnati Children’s paid \$2,879 and \$852 in income taxes for unrelated business income during the year ended June 30, 2025 and 2024, respectively.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Fiscal years 2022 through 2025 are subject to examination by both the Federal and State tax jurisdictions.

- (g) Cash Equivalents – Cash equivalents consist primarily of money market and money market mutual funds, demand deposits, and commercial paper investments with maturities of three months or less. Cash is held primarily in two financial institutions.
- (h) Inventories and Prepaid Expenses – Inventories consist primarily of medical supplies and pharmaceuticals and are valued on an average cost method.

As part of Cincinnati Children’s variable capitation agreement, reimbursement in 2024 was reduced by an actuarially determined estimate for incurred but not reported claims totaling \$20,555. The estimate is recorded as an increase in Prepaid expenses and an increase in Accounts payable and accrued expenses. In 2025, Cincinnati Children’s primary managed care organization returned funds held for incurred but not reported claims. At June 30, 2025 \$1,595 was included in Prepaid expenses.

- (i) Marketable Securities – Cincinnati Children’s accounts for its investments under ASC 958-320 “Not-for-Profit Entities – Investments – Debt Securities” and ASC 958-321 “Not-for-Profit Entities – Investments – Equity Securities.” Cincinnati Children’s carries its marketable securities at fair value with unrealized gains and losses included in Net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets.
- (j) Property and Equipment – Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

Land improvements	3-25 years
Buildings and building improvements	5-40 years
Equipment	3-25 years

Cincinnati Children’s evaluates long-lived assets under the provisions of ASC 360 “Property Plant and Equipment.” During fiscal years 2025 and 2024, Cincinnati Children’s did not incur any losses related to impairment of property and equipment.

- (k) Goodwill – Goodwill is the excess of the purchase price over the fair value of the net assets of an entity acquired. Cincinnati Children’s elected to apply the accounting alternatives available for not-for-profit entities. Goodwill is amortized over a 10-year period and tested for impairment at the entity level when a triggering event occurs. During the years ended June 30, 2025 and 2024, no amounts were recorded to goodwill and no impairment losses were recognized. During fiscal year 2025 and 2024, \$858 and \$858 of amortization expense was recognized as Depreciation and amortization, respectively.
- (l) Leases – Cincinnati Children’s leases property and equipment under finance and operating leases. Cincinnati Children’s determines if an arrangement is a lease at inception. Right-of-use assets and lease obligations are recognized for leases with terms greater than 12 months based on the net present value of the future minimum lease payments over the lease term at commencement date. When readily determinable, Cincinnati Children’s uses the interest rate implicit in the lease to determine the present value of future minimum lease payments. However, most of Cincinnati Children’s leases do not have a readily determinable implicit interest rate. For these leases, Cincinnati Children’s uses a collateralized incremental borrowing rate based on the period and cash payment stream comparable with that of each lease. The right-of-use asset and lease obligations include a value for options to extend a lease if it is reasonably certain that the option will be exercised.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

The current portion of operating lease obligations is included in the Current portion of long-term debt and lease obligations and the non-current portion is separately stated as Operating lease obligations on the Consolidated Balance Sheets. The related right-of-use assets are included in Operating lease right-of-use assets on the Consolidated Balance Sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in Purchased services in the Consolidated Statements of Operations and Changes in Net Assets.

The current portion of finance lease obligations is included in Current portion of long-term debt and lease obligations and the non-current portion is separately broken out as Finance lease obligations on the Consolidated Balance Sheets. The related finance lease right-of-use assets are included in Property and equipment, net on the Consolidated Balance Sheets. Finance lease right-of-use assets are amortized using the straight-line method over the shorter period of the lease term or the estimated useful life of the property or equipment. Such amortization expense is included in Depreciation in the Consolidated Statements of Operations and Changes in Net Assets.

- (m) Costs of Borrowing – Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal years 2025 and 2024, Cincinnati Children's capitalized \$4,662 and \$6,032 of interest related to construction in progress, respectively. Total cash paid for interest was approximately \$42,486 and \$38,046 in fiscal years 2025 and 2024, respectively.

Deferred bond issuance costs and issuance premiums are amortized using the effective interest method over the period the related obligation is outstanding.

- (n) Interest Rate Swap Agreement – Cincinnati Children's has an interest rate swap agreement to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. The swap agreement is measured at fair value and recognized in the Consolidated Balance Sheets within Other long-term assets. Cincinnati Children's recognizes gains and losses from the changes in fair value of the interest rate swap agreement as Non-operating gains within Net investment return on the Consolidated Statements of Operations and Changes in Net Assets.
- (o) Net Asset Classifications – Cincinnati Children's reports its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objective of the organization are classified as Net assets without donor restrictions. These net assets may be used at the discretion of Cincinnati Children's management.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors or supporting organizations are classified as Net assets with donor restrictions. Some restrictions are temporary in nature; those restrictions will be met by fulfilling a certain purpose or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the principal be maintained in perpetuity.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Net assets with donor restrictions are comprised of the following:

	2025	2024
Subject to expenditure for specified purpose:		
Clinical	\$ 38,900	\$ 42,014
Research	151,028	94,949
Education	19,946	19,165
General administration and other	31,389	32,054
	<u>241,263</u>	<u>188,182</u>
Subject to expenditure for specified purpose, held at supporting organizations:		
Research	17,754	16,850
Education	1,309	1,242
General administration and other	5,268	5,000
	<u>24,331</u>	<u>23,092</u>
Subject to expenditure based on Board discretion of the supporting organization, held at supporting organizations	<u>2,863,979</u>	<u>2,664,502</u>
	<u>2,863,979</u>	<u>2,664,502</u>
Investment in perpetuity, the income from which is expendable for specified purpose, held at Cincinnati Children's:		
Clinical	-	1,676
Research	-	23,800
Education	-	1,789
General administration and other	-	4,692
	<u>-</u>	<u>31,957</u>
Investment in perpetuity, the income from which is expendable for specified purpose, held at supporting organizations:		
Clinical	77,573	68,357
Research	2,833,936	2,560,685
Education	126,398	112,747
General administration and other	111,132	96,405
	<u>3,149,039</u>	<u>2,838,194</u>
Subject to appropriation and expenditure when a specified event occurs:		
Upon death of insured party	2,163	2,063
	<u>2,163</u>	<u>2,063</u>
Total net assets with donor restrictions	<u>\$ 6,280,775</u>	<u>\$ 5,747,990</u>

- (p) Revenue and Gains in Excess of Expenses – The Consolidated Statements of Operations and Changes in Net Assets subtotals operating revenues, gains and other support, operating expenses and nonoperating gains as Revenue and gains in excess of expenses. Other changes in net assets without donor restrictions are receipts from and transfers to supporting organizations, pension and post-retirement health liability adjustments, and Net assets released from restrictions used for purchase of property and equipment, which are excluded from Revenue and gains in excess of expenses.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

- (q) Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
- (r) New Accounting Pronouncements – In August 2023, the FASB issued ASU No 2023-05 (“Business Combinations – Joint Venture Formations” Subtopic 805-60). The amendments in this ASU are effective prospectively for all joint ventures with a formation date on or after January 1, 2025, and early adoption is permitted. Additionally, a joint venture that was formed before the effective date of the ASU may elect to apply the amendments retrospectively if it has sufficient information. The standard has been adopted and there are no material impacts to our Consolidated Financial Statements.

(2) Liquidity and Availability –

Financial assets available for general expenditure within one year of the balance sheet date consist of the following:

	<u>2025</u>	<u>2024</u>
Amounts available for general expenditure:		
Cash and cash equivalents	\$ 258,518	\$ 189,507
Marketable securities	1,315,026	1,335,526
Patient receivables, net	723,994	704,875
Other receivables	236,797	236,163
	<u>2,534,335</u>	<u>2,466,071</u>
Less: Board-designated assets	150,000	150,000
Financial assets available for general expenditure	<u>\$ 2,384,335</u>	<u>\$ 2,316,071</u>

Cincinnati Children’s has cash and cash equivalents, marketable securities (more fully described in Note 4), patient receivables and certain other receivables which are liquid and available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. During fiscal year 2021, the Board of Trustees designated \$100,000 plus interest and earnings from net assets without donor restrictions to be used to support Cincinnati Children’s community pillar of the *Pursuing Our Potential Together* strategic plan. During fiscal year 2023, the Board of Trustees designated \$50,000 for employee benefit initiatives. Cincinnati Children’s has other assets limited to use for professional liability, self-insurance health care and debt service, as well as various escrow accounts. These assets limited to use, which are more fully described in Notes 4 and 6, are not available for general expenditure within the next year and are not reflected in the amounts above.

Cincinnati Children’s has \$61,542 in outstanding obligations for which liquid funds must be available for payment in the event of a failed remarketing. Cincinnati Children’s maintains certain balances in cash and investments and has access to a \$200,000 line of credit, as discussed in more detail in Note 9.

Additionally, Cincinnati Children’s is required to maintain certain liquidity ratios as outlined in bond covenants. As of June 30, 2025 and 2024, Cincinnati Children’s was in compliance with all such covenants.

Cincinnati Children’s forecasts its future cash flows and monitors liquidity on an ongoing basis.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

(3) Reconciliation of Cash, Cash Equivalents, and Restricted Cash –

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the fiscal years ending June 30, 2025 and 2024:

	<u>2025</u>	<u>2024</u>
Cash and cash equivalents	\$ 258,518	\$ 189,507
Restricted cash included in assets limited as to use	20,512	8,229
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows	<u>\$ 279,030</u>	<u>\$ 197,736</u>

(4) Fair Value Measurements –

Cincinnati Children’s accounts for its assets and liabilities under ASC 820 “Fair Value Measurements.” As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using Cincinnati Children’s estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children’s utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2025.

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Marketable Securities:				
U.S. Government and agency securities	\$ -	\$ 135,228	\$ -	\$ 135,228
Foreign bonds	-	51,919	-	51,919
Municipal bonds	-	303	-	303
Common stock	338,147	-	-	338,147
Corporate obligations	-	248,580	-	248,580
ETFs	316,044	-	-	316,044
Commercial paper	-	17,799	-	17,799
Total marketable securities measured in the fair value hierarchy	654,191	453,829	-	1,108,020
High Yield fixed income ²	-	-	-	16,410
Core Plus fixed income ²	-	-	-	190,596
	<u>654,191</u>	<u>453,829</u>	<u>-</u>	<u>1,315,026</u>
Assets Limited As To Use:				
Money market mutual funds	20,512	-	-	20,512
Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):				
Common stock	12,389	-	-	12,389
Mutual funds:				
Money market	496	-	-	496
Equity	1,477	-	-	1,477
International equity	392	-	-	392
Bond	683	-	-	683
Lifecycle	9,160	-	-	9,160
Variable annuities	-	113	-	113
Guaranteed insurance contract	-	-	911	911
	<u>24,597</u>	<u>113</u>	<u>911</u>	<u>25,621</u>
Derivative Investments (included in Other-Long-term Assets):				
Interest rate swap agreement	-	2,592	-	2,592
Total investments at fair value	<u>\$ 699,300</u>	<u>\$ 456,534</u>	<u>\$ 911</u>	<u>\$ 1,363,751</u>

² Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2024.

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Marketable Securities:				
U.S. Government and agency securities	\$ -	\$ 193,301	\$ -	\$ 193,301
Foreign bonds	-	56,915	-	56,915
Municipal bonds	-	3,173	-	3,173
Common stock	300,187	-	-	300,187
Corporate obligations	-	349,932	-	349,932
ETFs	219,084	-	-	219,084
Commercial paper	-	35,259	-	35,259
Total marketable securities measured in the fair value hierarchy	<u>519,271</u>	<u>638,580</u>	-	1,157,851
Full discretion fixed income ³	-	-	-	177,675
	<u>519,271</u>	<u>638,580</u>	-	<u>1,335,526</u>
Assets Limited As To Use:				
Money market mutual funds	8,267	-	-	8,267
Common stock	31,919	-	-	31,919
	<u>40,186</u>	-	-	<u>40,186</u>
Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):				
Common stock	11,351	-	-	11,351
Mutual funds:				
Money market	247	-	-	247
Equity	1,097	-	-	1,097
International equity	356	-	-	356
Bond	633	-	-	633
Lifecycle	6,514	-	-	6,514
Variable annuities	-	25	-	25
Guaranteed insurance contract	-	-	718	718
	<u>20,198</u>	<u>25</u>	<u>718</u>	<u>20,941</u>
Derivative Investments (included in Other-Long-term Assets):				
Interest rate swap agreement	-	4,500	-	4,500
Total investments at fair value	<u>\$ 579,655</u>	<u>\$ 643,105</u>	<u>\$ 718</u>	<u>\$ 1,401,153</u>

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

The carrying amount and fair value of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

³ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Cincinnati Children’s uses quoted market prices in active markets to determine the fair value of common stock, mutual funds and ETFs; such items are classified as Level 1 in the fair value hierarchy.

Cincinnati Children’s primarily bases fair value for investments in fixed income securities, including U.S. government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate). Commercial paper is valued using broker quotes that utilize observable market inputs. Consideration is also given to the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Cincinnati Children’s interest rate swap agreement (Note 14) is a derivative instrument valued using the income approach, which uses market inputs to discount future cash flows to a single present amount based on market expectations.

High Yield fixed income represents an investment in a limited liability company whose investment objective is to achieve superior fixed income returns on invested funds through exposure to higher quality, less volatile high yield debt securities. As set forth in the LLC agreement, the company will dissolve on March 29, 2040, but may dissolve earlier under certain conditions. Any investing member may elect to withdraw, in whole or in part, from the company by providing thirty days’ notice. The High Yield fixed income investment is measured at fair value using the net asset value per share practical expedient.

Core Plus fixed income (formerly, Full Discretion fixed income) represents an investment in a limited liability company whose investment objective is to maximize risk-adjusted returns through exposure to a broad spectrum of fixed income investments, including investment grade securities, high yield securities, and emerging market bonds. As set forth in the LLC agreement, the company will dissolve on May 22, 2047, but may dissolve earlier under certain conditions. Any investing member may elect to withdraw, in whole or in part, from the company by providing sixty days’ notice, subject to the manager’s discretion. The Core Plus fixed income investment is measured at fair value using the net asset value per share practical expedient.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value, and is classified as Level 3 based on time restrictions for redemption.

Activity and transfers into and out of Level 3 and the reasons for those transfers are as follows:

<u>2025</u>	<u>Guaranteed Insurance Contracts</u>
Purchases	\$ 108
Issues	-
<u>2024</u>	<u>Guaranteed Insurance Contracts</u>
Purchases	\$ 117
Issues	-

Cincinnati Children’s policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2025 and 2024, there were no material transfers in or out of Levels 1, 2 or 3.

(5) **Losses on the Provision of Uncompensated Care** –

In accordance with its mission and purpose, Cincinnati Children’s maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children’s accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children’s defines uncompensated care as services rendered to patients whose families’ annual income or net worth falls below certain minimum standards. As such, losses absorbed by Cincinnati Children’s in rendering services to patients who are covered under governmental programs which are designed to aid low-income families (primarily the Medicaid program) are considered uncompensated care.

The following information summarizes uncompensated care provided during the years ended June 30, 2025 and 2024:

Charges	2025	2024
Charges under Medicaid and other entitlement programs	\$ 2,837,803	\$ 2,562,854
Charity care not eligible for Medicaid assistance, at established charges	37,190	25,803
Other uncollectible self-pay, at established charges	43,880	33,346
Total Medicaid, charity care and other uncollectible self-pay charges	<u>\$ 2,918,873</u>	<u>\$ 2,622,003</u>
Costs/Losses		
Estimated costs to provide uncompensated care	\$ (1,297,278)	\$ (1,144,535)
Reimbursement from Medicaid programs	779,072	724,594
Losses on the provision of uncompensated care	(518,206)	(419,941)
Funds received from Hospital Care Assurance Program (HCAP) ⁴ and tax levy	66,720	67,801
Losses on provision of uncompensated care, net of HCAP and tax levy	<u>\$ (451,486)</u>	<u>\$ (352,140)</u>

The 2025 and 2024 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from preliminary cost reports because the current year cost report is not yet available. Management does not believe the use of preliminary data would have a material impact on the amounts calculated above.

(6) Funds in Trust –

Cincinnati Children’s has certain funds, which are invested and held in trust for various specified purposes. Funds are carried at fair value with unrealized gains and losses included in Net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth as follows:

⁴ The Hospital Care Assurance Program (HCAP) is a State of Ohio program created to financially assist hospitals that care for a disproportionate share of low-income patients who are unable to pay for their own care.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

	June 30,	
	2025	2024
Self-insurance funds:		
Professional liability	\$ 158	\$ 158
Employee health and workers' compensation	503	453
Bond interest and principal escrow funds	7,226	7,618
Endowment funds held in perpetual trust	-	31,957
Escrow funds held for capital projects	12,506	-
Miscellaneous operations	119	-
	\$ 20,512	\$ 40,186

(7) Property and Equipment –

Property and equipment consists of the following:

	June 30,	
	2025	2024
Land	\$ 46,954	\$ 47,033
Land improvements	38,652	37,636
Buildings and building improvements	2,346,047	2,232,333
Equipment	844,133	829,528
Construction in progress	269,647	144,998
	3,545,433	3,291,528
Accumulated depreciation	(1,733,259)	(1,641,398)
Property and equipment, net	\$ 1,812,174	\$ 1,650,130

(8) Professional Liability –

Cincinnati Children's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The current self-insured retention for asserted claims is \$10,000 (\$30,000 in aggregate). Cincinnati Children's regularly purchases excess healthcare professional liability insurance on a claims-made basis at varying levels.

The actuarial present value of expected costs (including incurred but not reported claims) for the healthcare professional liability program of \$24,370 and \$25,943 for 2025 and 2024, respectively, is accrued in the accompanying Consolidated Balance Sheets. At June 30, 2025 and 2024, \$9,500 and \$8,500 of the total accrued liability is reported in Accounts payable and accrued expenses as the current portion, respectively. Accrued healthcare professional liability losses are discounted at a rate of 4% at June 30, 2025 and 2024. The costs of Cincinnati Children's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, drugs and other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Accrued losses funding levels are actuarially determined based on management's estimation of potential outstanding loss liabilities, payout patterns, and various other assumptions, and then adjusted to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense is \$12,636 and \$13,034 for fiscal years 2025 and 2024, respectively.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

(9) Debt –

Debt at June 30, 2025 and 2024 is summarized as follows:

	<u>2025</u>	<u>2024</u>
Series 2018BB commercial paper, taxable	\$ -	\$ 100,000
Bonds payable:		
Series 2014T, 4.268% due 2044, taxable	298,186	298,090
Series 2016X, 5.00%, due through 2032, net of unamortized premium of \$5,311 in 2025 and \$6,208 in 2024	56,700	57,546
Series 2016Y, 2.853% due 2026, taxable	99,903	99,817
Series 2018Z*, variable interest (2.30% at June 30, 2025), due through 2037	24,183	27,517
Series 2018AA*, variable interest (1.92% at June 30, 2025), due through 2037	37,359	42,506
Series 2019CC, 5.0% due through 2049, net of unamortized premium of \$50,629 in 2025 and \$53,062 in 2024	185,182	187,565
Series 2020DD, 2.82% due 2050, taxable	198,778	198,730
Series 2024EE, 2.934% due 2034	55,925	66,155
Total	<u>956,216</u>	<u>1,077,926</u>
Loans payable:		
Fixed interest 1%, due 2034	32,000	-
Fixed interest 1.2%, due 2054	20,990	-
Total	<u>52,990</u>	<u>-</u>
Less:		
Current portion of bonds and loans payable	(10,295)	(10,230)
Commercial paper notes	-	(100,000)
Bonds payable subject to remarketing, net	(61,542)	(70,023)
Bonds payable and loans payable - long-term	<u>\$937,369</u>	<u>\$897,673</u>

*Denotes variable rate bonds subject to remarketing agreements

- (a) Bonds Payable – Cincinnati Children's has pledged gross revenues to secure the payment of 2014T, 2016X, 2016Y, 2018Z, 2018AA, 2019CC, 2020DD, and 2024EE bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, and related agreements, including a requirement to maintain a minimum Debt Service Coverage Ratio.

The 2018Z and 2018AA tax-exempt bonds are subject to mandatory tender purchase seven days after notice from bondholders and may be remarketed. If the bonds are not remarketed, Cincinnati Children's must repay the bonds. The 2018Z and 2018AA bonds are classified as Current liabilities in Bonds payable subject to remarketing, net in the accompanying Consolidated Balance Sheets. The interest rates on the 2018Z and 2018AA variable rate bonds are reset weekly by a rate-setting agent.

- (b) Commercial Paper – The Series 2018BB taxable commercial paper was issued in the original aggregate principal amount of \$100,000 and outstanding at any one time in a principal amount not to exceed \$100,000. The notes shall mature no later than May 15, 2048. The commercial paper notes have a maximum maturity period of 270 days and are resold at maturity. In the event the notes have not been resold, Cincinnati Children's must repay the notes. The 2018BB commercial paper is recorded in

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Current liabilities in the accompanying Consolidated Balance Sheets. The interest rates on the 2018BB commercial paper are reset with each remarketing by a rate-setting agent. In fiscal year 2025, the outstanding commercial paper balance was paid, however the commercial paper program remains open and available for use.

- (c) Future Debt Maturities – The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

2025	\$ 72,160
2026	110,160
2027	10,120
2028	16,270
2029	17,030
Thereafter	732,315
	<u>\$ 958,055</u>

- (d) Line of Credit – Cincinnati Children's maintains an agreement for a line of credit of \$200,000. The line of credit agreement was amended in May 2025 to extend the maturity date to May 2028. The line of credit bears interest at the greater of the Overnight Bank Funding Rate plus 60 basis points, the Prime Rate or the Daily Simple SOFR Rate plus 100 basis points. \$24,550 of the line of credit has been committed to secure letters of credit as required by a payer arrangement, leaving \$175,450 available. There were no draws on the line of credit during fiscal year 2025 or 2024.
- (e) Loans Payable – In September 2024, Cincinnati Children's entered into a loan agreement of \$32,000 to be used towards the purchase of a building, which serves as collateral for the loan. The loan matures in 10 years and bears interest at a rate of 1% per annum. Subject to the achievement of certain performance metrics, \$2,000 of the principal may be forgiven on December 31, 2033.

In November 2024, Cincinnati Children's entered into a financing arrangement to fund a capital project. The loan payable is to a group of qualified community development entities, through an investment fund, bearing interest at 1.2% annually, and totals \$20,990 as of June 30, 2025.

- (10) Employee Benefit Plans –

Cincinnati Children's maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children's funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children's announced an amendment to the defined benefit plan in September 2024. The amendment froze the defined benefit plan for new entrants effective January 1, 2025 and current participants effective December 31, 2025, at which time benefits will cease to accrue in the defined benefit plan. New eligible employees were offered a 401(a) defined contribution plan beginning January 1, 2025, while current defined benefit plan participants will be eligible to participate in the defined contribution plan beginning January 1, 2026.

Curtailed accounting was triggered due to the accrual freeze resulting in a plan remeasurement as of September 30, 2024. The resulting curtailment gain of \$24,161, which reduced the net periodic cost and improved the funded position, is recorded in Net benefit gain other than service cost in the Consolidated Statements of Operations and Changes in Net Assets.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Cincinnati Children’s investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status, and corporate financial condition. In February 2024, Cincinnati Children’s adopted a temporary Investment Policy designed to reduce return-seeking assets over time. The intent is to balance the portfolio heavily towards liability-hedging assets to reduce funded status volatility due to interest rate movements. No additional capital will be committed to illiquid asset classes.

Cincinnati Children’s has adopted allocation targets within the return-seeking and liability hedging portfolios as follows:

	<u>Min - Max</u>
Return-Seeking Allocation:	0% - 26%
Liability-Hedging Allocation:	74% - 100%
Intermediate Duration	0% - 100%
Long Credit	0% - 100%
STRIPS (Long Duration Treasury Instruments)	0% - 50%

In order to maintain the portfolio’s actual asset allocation in line with the target allocations specified above, rebalancing will occur periodically.

Cincinnati Children’s defined benefit plan investment allocation at the actuarial measurement date of June 30, 2025 and 2024 by asset category is as follows:

	<u>2025</u>	<u>2024</u>
Cash and cash equivalents	1.4%	3.1%
Corporate bonds	-	13.7%
Government bonds	-	2.4%
Investment Partnerships:		
Equity	3.9%	4.7%
Real estate	2.2%	2.5%
Commingled Investment Funds:		
Bond	73.4%	51.4%
Government	19.1%	22.2%
	<u>100.0%</u>	<u>100.0%</u>

The fair values of Level 1 investments are based on quoted prices in active markets.

The fair value for investments in fixed income securities, including U.S. government securities and corporate obligations, is based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Investments in partnerships – U.S. equities and real estate – are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Commingled investment funds are private funds for institutional investors valued at net asset value. The commingled funds primarily invest in actively traded bond mutual funds and US Treasury STRIPS with daily liquidity and no lockup period.

There were no transfers between levels in fiscal year 2025 or fiscal year 2024.

At June 30, 2025, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Cash and cash equivalents	\$ 16,853	\$ -	\$ -	\$ 16,853
Corporate bonds	-	-	-	-
Government bonds	-	-	-	-
Total assets in the fair value hierarchy	<u>16,853</u>	<u>-</u>	<u>-</u>	<u>16,853</u>
Investments measured at net asset value ⁵ :				
Investment Partnerships:				
Equity	-	-	-	47,353
Real estate	-	-	-	26,774
Commingled Investment Funds:				
Bond	-	-	-	891,423
Government	-	-	-	231,609
Total assets at fair value	<u>\$ 16,853</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,214,012</u>

At June 30, 2024, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Cash and cash equivalents	\$ 38,616	\$ -	\$ -	\$ 38,616
Corporate bonds	-	169,040	-	169,040
Government bonds	-	29,668	-	29,668
Total assets in the fair value hierarchy	<u>38,616</u>	<u>198,708</u>	<u>-</u>	<u>237,324</u>
Investments measured at net asset value ⁶ :				
Investment Partnerships:				
Equity	-	-	-	57,968
Real estate	-	-	-	31,018
Commingled Investment Funds:				
Bond	-	-	-	636,962
Government	-	-	-	275,419
Total assets at fair value	<u>\$ 38,616</u>	<u>\$ 198,708</u>	<u>\$ -</u>	<u>\$ 1,238,691</u>

⁵ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

⁶ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

As of June 30, 2025, Cincinnati Children's has made \$93,900 in funding commitments in nine investment partnerships, of which \$76,800 has been funded. Additionally, Cincinnati Children's has made \$72,500 in funding commitments in nine real estate investment partnerships, of which \$68,900 has been funded. It is anticipated that these commitments will be funded from liquid investments of the plan.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

	<u>2025</u>	<u>2024</u>
Discount rate used to determine actuarial present value of the projected benefit obligation	5.92%	5.73%
Assumed rate of increase in compensation levels	3.50%	3.50%
Long-term rate of return	6.00%	6.00%

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2025 and 2024, utilizing actuarial measurement dates as of June 30, 2025 and 2024.

	<u>2025</u>	<u>2024</u>
Change in projected benefit obligation:		
Projected benefit obligation at beginning of year	\$ 1,106,187	\$ 1,093,652
Service cost	46,847	48,165
Interest cost	59,618	58,430
Other actuarial gain	(4,814)	(39,608)
Benefits paid	(58,350)	(54,452)
Curtailments	(38,394)	-
Projected benefit obligation at end of year	<u>\$ 1,111,094</u>	<u>\$ 1,106,187</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ 1,238,691	\$ 1,279,650
Actual return (loss) on plan assets	33,671	13,493
Benefits paid	(58,350)	(54,452)
Fair value of plan assets at end of year	<u>1,214,012</u>	<u>1,238,691</u>
Funded status	<u>102,918</u>	<u>132,504</u>
Net accrued pension benefit asset in consolidated balance sheets	<u>\$ 102,918</u>	<u>\$ 132,504</u>

For the Retirement Plan, the overall actuarial gain in plan obligation of \$4,814 is primarily attributable to an increase in the discount rate between June 30, 2024 and June 30, 2025. The discount rate increase of 65 basis points resulted in a decrease in benefit obligation of approximately \$30,768 while new entrants to the plan resulted in an increase in benefit obligation of approximately \$18,854.

In 2025 and 2024, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial gain in fiscal years 2025 and 2024.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Amounts included in Net Assets without donor restrictions but not yet recognized in pension cost consist of:

	<u>2025</u>	<u>2024</u>
Net actuarial loss	\$ 291,124	\$ 304,807
Net prior service credit	(5,876)	(41,788)
Accumulated other comprehensive loss	<u>\$ 285,248</u>	<u>\$ 263,019</u>

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

	<u>2025</u>	<u>2024</u>
Discount rate used to determine benefit costs:		
July – September	5.73%	5.53%
October – June	5.27%	5.53%
Assumed rate of increase in compensation levels	3.50%	4.00%
Expected long-term rate of return on plan assets	6.00%	6.00%

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Net periodic pension cost for 2025 and 2024 related to the defined benefit plan consisted of the following components:

	<u>2025</u>	<u>2024</u>
Service cost	\$ 46,847	\$ 48,165
Interest cost	59,618	58,430
Expected return on plan assets	(76,112)	(84,667)
Amortization of prior service credit	(11,751)	(11,751)
Amortization of net loss	12,916	-
Net periodic pension cost	<u>\$ 31,518</u>	<u>\$ 10,177</u>
Curtailement gain	(24,161)	-
Disclosed net benefit cost	<u>7,357</u>	<u>10,177</u>

Based on preliminary estimates, we do not expect any required fiscal year 2025 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was \$1,107,041 and \$1,066,845 at June 30, 2025 and 2024, respectively.

Cincinnati Children's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

2026	\$ 80,252
2027	74,857
2028	72,971
2029	71,796
2030	70,771
2031-2035	340,160

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

All other retirement plans maintained by Cincinnati Children’s are defined contribution plans. Cincinnati Children’s contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense, net of forfeitures, related to these other plans was approximately \$38,609 and \$35,876 in fiscal years 2025 and 2024, respectively.

Cincinnati Children’s provides individual nonqualified deferred compensation benefits to key employees with varying terms. Accounts are participant-directed, and the amounts are at a substantial risk of forfeiture and revert back to the Cincinnati Children’s if the employee does not meet certain criteria as established by the plan. The amount of deferred compensation income and expense resulting from changes in market value of underlying investments are recognized in fiscal years 2025 and 2024 was \$1,019 and \$3,420, respectively. The current portion of plan accounts are included in Other receivables with a corresponding liability in Accounts payable and accrued expenses on the Consolidated Balance Sheets. The long-term portion of plan accounts are included in Other long-term assets with a corresponding liability in Other long-term liabilities on the Consolidated Balance Sheets.

The following table displays the nonqualified deferred compensation plans assets and liabilities as of June 30, 2025 and 2024:

	2025	2024
Current portion	\$ 697	\$ 52
Long-term portion	24,924	20,889
Total assets and liabilities	<u>\$ 25,621</u>	<u>\$ 20,941</u>

(11) Commitments and Contingencies –

- (a) Litigation – Cincinnati Children’s is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC 450, “Contingencies.” After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children’s.
- (b) Laws and Regulations – The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations guide the healthcare industry in many domains such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient service, and Medicare and Medicaid fraud and abuse to name a few. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, is complex and can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Management believes that Cincinnati Children’s is in compliance, in all material respects, with fraud and abuse as well as other applicable government laws and regulations. Cincinnati Children’s has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient service.
- (c) Capital Commitments – Cincinnati Children’s has entered into agreements with general contractors for several new construction projects, renovations, equipment, and information system technology projects. Approximately \$1,072,216 has been spent through June 30, 2025 and approximately \$639,396 is expected to be spent in connection with current active projects. The commitments have expected completion dates ranging from fiscal year 2026 through fiscal year 2032.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

- (d) Funding Commitments – The Board of Trustees of Cincinnati Children’s approved revocable commitments for up to \$20,000 in non-recourse loans to Uptown Consortium Inc. Cincinnati Children’s has provided \$17,867 of funding in relation to these commitments through June 30, 2025. Management does not anticipate any additional funding. These funds are used to invest in commercial and residential projects in the uptown area. During fiscal year 2025, none of the loans were repaid. Cincinnati Children’s expects to receive an additional \$8,773 related to the loans which is recorded to Other long-term assets.
- (e) Investment Commitments – Cincinnati Children’s has made commitments to invest \$35,500 in eight limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology, advanced manufacturing, and healthcare. Cincinnati Children’s has made commitments to invest \$26,902 in sixteen limited liability companies that focus on investing in early-stage venture capital funds regionally and nationally with the goals of making the Cincinnati region the place for entrepreneurs and investors to launch new ideas and driving capital into scalable technology companies in southwest Ohio. Investment values are included in Other assets in the Consolidated Balance Sheets. Cincinnati Children’s occasionally receives distributions from these investments which reduce investment values.

The following displays the amounts funded and investment values at June 30, 2025 and 2024:

<u>2025</u>	<u>Funded</u>	<u>Value</u>
Investment in Limited Partnerships	\$ 24,646	\$ 21,194
Investments in Limited Liability Corporations	19,965	22,707
Total	<u>\$ 44,611</u>	<u>\$ 43,901</u>
<u>2024</u>	<u>Funded</u>	<u>Value</u>
Investment in Limited Partnerships	\$ 29,670	\$ 15,286
Investments in Limited Liability Corporations	16,605	20,953
Total	<u>\$ 46,275</u>	<u>\$ 36,239</u>

(12) Leases –

Cincinnati Children’s leases certain property and equipment. Cincinnati Children’s determines if an arrangement is a lease at inception of a contract.

The following table presents expenses recorded related to lease arrangements for the years ended June 30, 2025 and 2024:

	<u>2025</u>	<u>2024</u>
Operating lease expense	\$ 4,274	\$ 3,806
Finance leases:		
Amortization of right-of-use assets	7,412	8,150
Interest on finance lease obligations	1,625	1,871
Short-term and variable lease expense	5,710	5,461
Total lease expense	<u>\$ 19,021</u>	<u>\$ 19,288</u>

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

Other information related to leases for the years ended June 30, 2025 and 2024 is as follows:

Supplemental Cash Flow Information

Cash paid for amounts included in the measurement of lease liabilities:

	<u>2025</u>	<u>2024</u>
Operating cash flows from operating leases	\$ 2,992	\$ 3,062
Financing cash flows from finance leases	7,073	6,827

Weighted Average Remaining Lease Term (in Years)

	<u>2025</u>	<u>2024</u>
Operating leases	8.1	9.0
Finance leases	6.8	7.5

Weighted Average Discount Rate

	<u>2025</u>	<u>2024</u>
Operating leases	5.72%	5.55%
Finance leases	3.61%	3.61%

The aggregate future lease payments for operating and finance leases as of June 30, 2025 are as follows:

	<u>Operating</u>	<u>Finance</u>
2026	\$ 4,305	\$ 8,196
2027	3,709	7,107
2028	2,592	6,053
2029	2,594	5,351
2030	2,563	5,485
Thereafter	10,245	14,318
Total lease payments	<u>26,008</u>	<u>46,510</u>
<u>Present values:</u>		
Current lease liabilities	3,161	6,825
Long-term lease liabilities	17,241	34,378
Total lease liabilities	<u>20,402</u>	<u>41,203</u>
Difference between undiscounted cash flows and discounted cash flows	<u>\$ 5,606</u>	<u>\$ 5,307</u>

(13) Functional Expenses –

The costs associated with delivering services at Cincinnati Children's are presented by functional category in the tables below. To reflect this, certain expenses have been allocated across functions based on methodologies deemed equitable by management. These allocation methods are reviewed annually by management, who may revise them as new information becomes available. Updates to the allocation approach during the year ended June 30, 2025 did not result in a material impact on the expense distribution shown.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

The expenses that are allocated include the following:

<u>Expense</u>	<u>Method of Allocation</u>
Depreciation	Square footage
Utilities	Square footage

The following presents expenses by both their nature and function for the year ended June 30, 2025:

	<u>Clinical</u>	<u>Research</u>	<u>Education</u>	<u>Fundraising</u>	<u>Management and General</u>	<u>Total</u>
Salaries	\$ 1,199,517	\$ 234,407	\$ 37,212	\$ 6,016	\$ 304,494	\$ 1,781,646
Employee benefits	319,193	62,527	9,190	1,676	57,927	450,513
Supplies, drugs and other	440,041	80,266	5,863	716	99,963	626,849
Purchased services	126,265	57,970	4,971	2,138	193,504	384,848
Depreciation and amortization	94,095	33,261	1,111	423	30,026	158,916
Utilities	15,035	5,315	177	68	4,798	25,393
Interest	-	-	-	-	30,416	30,416
	<u>\$ 2,194,146</u>	<u>\$ 473,746</u>	<u>\$ 58,524</u>	<u>\$ 11,037</u>	<u>\$ 721,128</u>	<u>\$ 3,458,581</u>

The following presents expenses by both their nature and function for the year ended June 30, 2024:

	<u>Clinical</u>	<u>Research</u>	<u>Education</u>	<u>Fundraising</u>	<u>Management and General</u>	<u>Total</u>
Salaries	\$ 1,089,638	\$ 221,048	\$ 69,932	\$ 4,641	\$ 283,444	\$ 1,668,703
Employee benefits	247,466	54,287	17,202	1,290	110,779	431,024
Supplies, drugs and other	457,823	42,980	3,613	568	94,231	599,215
Purchased services	132,109	61,566	3,018	737	179,436	376,866
Depreciation and amortization	82,879	35,140	168	375	34,202	152,764
Utilities	11,951	5,067	24	54	4,932	22,028
Interest	-	-	-	-	32,860	32,860
	<u>\$ 2,021,866</u>	<u>\$ 420,088</u>	<u>\$ 93,957</u>	<u>\$ 7,665</u>	<u>\$ 739,884</u>	<u>\$ 3,283,460</u>

(14) Interest Rate Swap Agreement –

In August 2019, Cincinnati Children's entered into a 10-year interest rate swap agreement in which Cincinnati Children's and the counterparty agree to exchange the difference between fixed rate and variable rate interest amounts calculated by reference to specified notational principal amounts during the agreement period. The objective is to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. Parties to interest rate swap agreements are subject to market risk for changes in interest rates and risk of credit loss in the event of nonperformance by the counterparty.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024, respectively (dollars in thousands)

The following table summarizes the general terms of Cincinnati Children's fixed payment swap agreement as of June 30, 2025:

<u>Effective</u>	<u>Expiration</u>	<u>Counterparty</u>	<u>Interest Rate Paid</u>	<u>Interest Rate Received</u>	<u>Notational Amount</u>
August 2019	August 2029	Fifth Third Bank	1.38%	USD-SIFMA Municipal Swap Index, 1.92% at June 30 th	\$ 61,865

As of June 30, 2025 and 2024 the swap fair value of \$2,592 and \$4,500 was recorded in Other long-term assets in the accompanying Consolidated Balance Sheets, respectively.

(15) Subsequent Events –

Management reviewed subsequent events through September 30, 2025, the date the Consolidated Financial Statements were issued, noting no changes are required to the Consolidated Financial Statements or footnotes.

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure						
Department of Defense	DOD	Military Medical Research and Development	Cardiac Rhabdomyomas as Biomar				HT94252310212	12.420	\$ -	\$ 64,214	\$ 64,214						
			Combinatorial targeting of big				HT94252310453	12.420	-	457,450	457,450						
			Spreading depolarizations as a	University of Cincinnati		015141-00002	HT94252310483	12.420	-	22,108	22,108						
			SPR400027: Ogbu - MSU Sub - Lupus DoD RC115795-CCHMC SPR4000 10/01/2023 (version 0)	Michigan State University		RC115795-CCHMC	HT94252310937	12.420	-	4,208	4,208						
			Novel RAC Pathway Inhibitors f		Dana Farber Cancer Institute		HT94252310960	12.420	9,539	\$ 295,333	304,872						
			Targeting Schwann cell-immune				HT94252410435	12.420	-	127,227	127,227						
			Family-Centered e-Health Inter		Research Inst. at Nationwide Hos		HT94252410746	12.420	30,157	\$ 129,121	159,278						
			Follicular T cell targeting in				HT94252410964	12.420	-	246,688	246,688						
			Antioxidant Therapy with N-Ace				W81XWH2010139	12.420	-	178,636	178,636						
			Merlin-ASPP2 Tumor Suppressor				W81XWH2010377	12.420	-	96,095	96,095						
			Inflammatory vigor in heteroge				W81XWH2010392	12.420	-	4,097	4,097						
			CHIPS (CH11ed Platelet Study)	University of Pittsburgh			W81XWH2190014	12.420	-	90,291	90,291						
			Regulating Together: Randomize		University of Alabama		W81XWH2210168	12.420	40,389	\$ 510,694	551,083						
			Regulation of Translation by N				W81XWH2210196	12.420	-	22,292	22,292						
			Trial of Indication-based Tran	Children's Hospital Boston			W81XWH2210301	12.420	-	65,041	65,041						
			Defects in the transition from		The University of TX Health Science		W81XWH2210410	12.420	23,686	\$ 179,625	203,311						
			Is There a Point of Convergence				W81XWH2210533	12.420	-	278,686	278,686						
			Establishing Network Connectiv				W81XWH2210633	12.420	-	184,569	184,569						
			SPR301332: Bender PH1-COG ALTE21C1 [AR71746] SPR301332 07/15/2022 (version 0)	Public Health Institute			W81XWH2210665	12.420	-	1,559	1,559						
			Human and mouse models of DDX4				W81XWH2210805	12.420	-	230,004	230,004						
			Delayed outcome mechanisms in				W81XWH2211075	12.420	-	379,588	379,588						
			Neuroinflammation Research Pro	University of Alabama-Birmingham			W81XWH2230001	12.RD	-	\$ 18,235	18,235						
			Military Medical Research and Development Total									103,771	3,585,761	3,689,532			
			Research and Technology Development			Systems Biological Assessment	Stanford University Medical Center		63182657-245431	W91NF2320019	12.910	-	26,629	26,629			
			Research and Technology Development Total									-	26,629	26,629			
			Department of Defense Total									103,771	3,612,390	3,716,161			
			Department of Education	DOE	Education Research, Development and Dissemination	Longitudinal Evaluation of Slu				R305A200028	84.305	-	165,135	165,135			
						SPR400053: Becker IES OTMP Sub to SCH - Resub 13416SUB SPR400 07/01/2024 (version 0)	Seattle Children's			13416SUB	R305A240106	84.305A	-	48,472	48,472		
						Education Research, Development and Dissemination Total									-	213,607	213,607
						Research in Special Education		UCSF Medical Center		R324A240199	R324A240199	84.324	124,014	157,817	281,831		
						Research in Special Education Total									124,014	157,817	281,831
			Department of Education	DOE	Special Education Grants to States	SPR301072: 06.29.2023_Riddle_Life Course Nexus GR134035 SPR30 07/01/2023 (version 0)	Ohio State University		GR134035	H027A210111	84.027A	-	15,879	15,879			
						SPR400152: Becker IES ADHD Children's Ntl Sub - Resub 3000866 07/01/2024 (version 0)	Children's National Medical Center			30008663-02	R324A240155	84.324A	-	168,525	168,525		
Special Education Grants to States Total									-	184,404	184,404						
Department of Education Total									124,014	555,828	679,842						
Department of Justice	DOJ	Crime Victim Assistance	VOCA 2024				Shapiro_VOCA_2024	15POVC-23-GG-00458-ASSI	16.575	-	54,511	54,511					
			Crime Victim Assistance Total									-	54,511	54,511			
			Edward Byrne Memorial Justice Assistance Grant Program		BJA Police Response Training f	The Arc of The United States INC		BJA Police Response Riddl	BJA Police Response	16.738	-	1,565	1,565				
Edward Byrne Memorial Justice Assistance Grant Program Total									-	1,565	1,565						
Department of Justice Total									-	56,076	56,076						
National Science Foundation	NSF	Biological Sciences	NSF/MCB-BSF: Modeling the mee		University of Cincinnati			2114950 47.074	14,235	274,885	289,120						
			Biological Sciences Total									14,235	274,885	289,120			
			Engineering Grants		Collaborative Research: Unders				2140441 47.041	-	36,542	36,542					
			Engineering Grants Total									-	36,542	36,542			
			Social, Behavioral, and Economic Sciences		A Contextual Analysis of Peer	University of Buffalo		R1352161		2234666 47.075	-	43,455	43,455				
Social, Behavioral, and Economic Sciences Total									-	43,455	43,455						
National Science Foundation Total									14,235	354,882	369,117						
Dept of Health and Human Serv	NIH	Aging Research	Novel mechanism of intestinal		Tulane University			R01AG063967	93.866	-	70,826	70,826					
			Accelerating research to advan					R01AG077497	93.866	-	815,969	815,969					
			Coordinated mechanisms to resc		Univer of Texas Medical Branch Galveston				R01AG078174	93.866	52,496	386,743	439,239				
			Myonuclear dynamics during ske						R01AG082697	93.866	-	494,465	494,465				
			SPR301083: UC Subaward R01_Lao 015438-00002 SPR301083 08/01/2023 (version 0)	University of Cincinnati			015438-00002	R01AG083164	93.866	-	30,394	30,394					
			Aging Research Total									52,496	1,798,397	1,850,893			
			Allergy, Immunology and Transplantation Research		Silencer Control of T cell Hom				F30A1157421	93.855	-	28,363	28,363				
			Allergy, Immunology and Transplantation Research		Mechanisms of Longitudinal Mic				F30A1181481	93.855	-	38,501	38,501				
			Allergy, Immunology and Transplantation Research		SPR400100: Valez F30 - Submission F30A1188599 SPR400100 11/18/2024 (version 0)					F30A1188599	93.855	-	18,221	18,221			
Allergy, Immunology and Transplantation Research		Maternal B cells enforce fetal					K08A1180350	93.855	-	179,985	179,985						

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
NIH	Allergy, Immunology and Transplantation Research		Improving Anaphylaxis Outcomes				K23AI175525	93.855	\$ -	\$ 186,374	\$ 186,374
NIH	Allergy, Immunology and Transplantation Research		Molecular Mechanisms of the Dy	Univ of Texas Medical Branch-Galveston		21-85495-01	P01AI150585	93.855	-	225,861	225,861
NIH	Allergy, Immunology and Transplantation Research		Combinatory Effects of Genetic				R00AI158660	93.855	-	321,346	321,346
NIH	Allergy, Immunology and Transplantation Research		Genetic Linkage in Lupus		Cincinnati Education & Research for Veterans Foundation		R01AI024717	93.855	222,750	414,075	705,637
					LaJolla Inst for Allergy and Immunology				68,812	-	-
NIH	Allergy, Immunology and Transplantation Research		Regulation of Gastrointestinal				R01AI045898	93.855	-	284,115	284,115
NIH	Allergy, Immunology and Transplantation Research		Epidemiologic Impact of HPV Va		Albert Einstein College of Medicine		R01AI104709	93.855	78,395	113,828	223,106
					Indiana University				30,883	-	-
NIH	Allergy, Immunology and Transplantation Research		Innate mechanisms of regulatio				R01AI123176	93.855	-	478,493	478,493
NIH	Allergy, Immunology and Transplantation Research		Genetic and Immunological Dis				R01AI124355	93.855	-	549,219	549,219
NIH	Allergy, Immunology and Transplantation Research		Food Allergy Outcomes Related	Northwestern University Medical School		60061589 CC	R01AI130348	93.855	-	103,136	103,136
NIH	Allergy, Immunology and Transplantation Research		SPR300058: Danziger - Arkansas Dominic (#034146-006/R01AI1390 03/08/2022 (version 0)	Arkansas Children's Hospital		#034146-006/R01AI139032	R01AI139032	93.855	-	6,518	6,518
NIH	Allergy, Immunology and Transplantation Research		SPR200480: Rothenberg Sub of Wake Forest-Jensen R01AI139126 S 07/01/2018 (version 0)	Wake Forest University Health Sciences			R01AI139126	93.855	-	18,877	18,877
NIH	Allergy, Immunology and Transplantation Research		Progesterone induced immune mo		ICAHN School of Medicine at Mount Sinai		R01AI145840	93.855	776,530	750	777,280
NIH	Allergy, Immunology and Transplantation Research		Rapid, safe suppression of IgE	University of Cincinnati		012329-00005	R01AI145991	93.855	-	9,076	9,076
NIH	Allergy, Immunology and Transplantation Research		Targeting natural killer cells		Duke University		R01AI148080	93.855	127,527	19,392	146,919
NIH	Allergy, Immunology and Transplantation Research		Roles of FFAR 3-SCFA axis in T				R01AI148138	93.855	-	333,983	333,983
NIH	Allergy, Immunology and Transplantation Research		Genomics of Inflammatory Bowel		Brigham and Women's Hospital		R01AI148276	93.855	6,472	520,719	536,407
					Emory University				4,304	-	-
					University of Cincinnati				4,912	-	-
NIH	Allergy, Immunology and Transplantation Research		An experimentally-refined, dyn				R01AI153442	93.855	-	787,424	787,424
NIH	Allergy, Immunology and Transplantation Research		Immunobiology of Influenza Vir	Children's Hospital Boston		GENFD0002024871	R01AI154470	93.855	-	25,883	25,883
NIH	Allergy, Immunology and Transplantation Research		Proteasome targeting for aller	University of Pennsylvania		580121	R01AI154932	93.855	-	377,772	377,772
NIH	Allergy, Immunology and Transplantation Research		Regulation of TLR signaling, I		Univ of Texas Southwestern		R01AI155426	93.855	63,045	431,858	494,903
NIH	Allergy, Immunology and Transplantation Research		Regulation of C. difficile col	University of Cincinnati		013939-00002	R01AI158451	93.855	-	2,183	2,183
NIH	Allergy, Immunology and Transplantation Research		Pay-it-forward gonorrhea testi	University of North Carolina		5123479/1R01AI158826-01	R01AI158826	93.855	-	57,511	57,511
NIH	Allergy, Immunology and Transplantation Research		Multi-Center Molecular Diagnos	Arkansas Children's Hospital			R01AI159684	93.855	-	1,080	1,080
NIH	Allergy, Immunology and Transplantation Research		Mechanisms of staphylococcal s	University of Nebraska Medical Center		34-5301-2210-201	R01AI162964	93.855	-	203,768	203,768
NIH	Allergy, Immunology and Transplantation Research		Leveraging Health Information	Children's National Medical Center		30007046	R01AI163232	93.855	-	14,166	14,166
NIH	Allergy, Immunology and Transplantation Research		Hyperhydration to Improve Kida	University of Calgary		R01AI165327	R01AI165327	93.855	-	84,154	84,154
NIH	Allergy, Immunology and Transplantation Research		Malaria associated pathogenesi	Indiana University		9671_CCHMC	R01AI165946	93.855	-	10,322	10,322
NIH	Allergy, Immunology and Transplantation Research		Commensal Candida albicans pri		Brown University		R01AI168222	93.855	438,376	488,727	927,103
NIH	Allergy, Immunology and Transplantation Research		Kruppel-like factor-2 CD4+ T c				R01AI172960	93.855	-	875,374	875,374
NIH	Allergy, Immunology and Transplantation Research		Gene regulatory network modeli		University of California Irvine		R01AI173314	93.855	256,298	486,295	742,593
NIH	Allergy, Immunology and Transplantation Research		Biochemical mechanisms for sust	University of Pennsylvania		587137	R01AI175185	93.855	-	20,064	20,064
NIH	Allergy, Immunology and Transplantation Research		Pregnancy induced decetylatio				R01AI175431	93.855	-	604,991	604,991
NIH	Allergy, Immunology and Transplantation Research		Blocking granzyme-mediated inm		Emory University		R01AI176519	93.855	327,373	302,005	629,378
NIH	Allergy, Immunology and Transplantation Research		The TNF Superfamily Control of				R01AI177359	93.855	-	482,159	482,159
NIH	Allergy, Immunology and Transplantation Research		Sialylated antibody defense ag				R01AI181778	93.855	-	696,159	696,159
NIH	Allergy, Immunology and Transplantation Research		SPR400304: Dr. Koichi Araki R01 - Resubmission due 7/5/2024 1 03/19/2025 (version 0)				R01AI184466	93.855	-	142,432	142,432
NIH	Allergy, Immunology and Transplantation Research		Parity, paternity and pregnanc				R01AI184537	93.855	-	465,129	465,129
NIH	Allergy, Immunology and Transplantation Research		Viral and Cellular Determinant				R01AI186611	93.855	-	608,169	608,169
NIH	Allergy, Immunology and Transplantation Research		Simplifying the transformation				R03AI185587	93.855	-	88,561	88,561
NIH	Allergy, Immunology and Transplantation Research		Genetic ancestry differences i				R21AI157363	93.855	-	3,524	3,524
NIH	Allergy, Immunology and Transplantation Research		Decoding human T-cell allospec	University of Notre Dame		204631CCHMC	R21AI169863	93.855	-	33,280	33,280
NIH	Allergy, Immunology and Transplantation Research		Early life: dysbiosis, and skin	University of Cincinnati		015692-00002	R21AI176276	93.855	-	129,221	129,221
NIH	Allergy, Immunology and Transplantation Research		Role of Innate Lymphocytes in				R21AI178517	93.855	-	310,023	310,023
NIH	Allergy, Immunology and Transplantation Research		SPR400130: R21-Norovirus_Hagan and Singh - Resubmission - 1 R 12/01/2024 (version 0)		Indiana University		R21AI183058	93.855	-	62,768	62,768
NIH	Allergy, Immunology and Transplantation Research		SPR400258: Hagan R21- sub with IU 1R21AI191085-01 SPR400258 02/25/2025 (version 0)				R21AI191085	93.855	5,303	56,181	61,484
NIH	Allergy, Immunology and Transplantation Research		USIDNET: A resource for clinic	Children's Hospital of Philadelphia		GRT-00002464	R24AI171055	93.855	-	41,407	41,407
NIH	Allergy, Immunology and Transplantation Research		SPR400256: 9.18.2023_Wagner_Sub to UCSF 15783ac SPR400256 09/03/2024 (version 0)	University of California, San Francisco		15783ac	R24AI184316	93.855	-	11,560	11,560
NIH	Allergy, Immunology and Transplantation Research		Dr. Ming Tan sub on an NIH STT	Scaled Microbiomics, LLC		SMB-CCHMC- 2023-001	R41AI172485	93.855	-	14,182	14,182
NIH	Allergy, Immunology and Transplantation Research		SPR400945: Thyross STTR-Bernstein_2022 1005 CHMC SPR400045 06/01/2024 (version 0)	Thyross, Inc		1005 CHMC	R42AI177202	93.855	-	268,850	268,850
NIH	Allergy, Immunology and Transplantation Research		SPR400234: Porello R61/R33 Sub UC Cushion 016342-00002 SPR400 12/20/2024 (version 0)	University of Cincinnati		016342-00002	R61AI187113	93.855	-	13,989	13,989
NIH	Allergy, Immunology and Transplantation Research		Vaccinology Training Program				T32AI165396	93.855	-	269,888	269,888
NIH	Allergy, Immunology and Transplantation Research		Gene therapy for SCID-X1 with	Children's Hospital Boston		GENFD0002491271	U01AI125051	93.855	-	12,307	12,307
NIH	Allergy, Immunology and Transplantation Research		Controlling and Preventing Asthma Progression and Severi	Children's Hospital Boston		GENFD0001867991	U01AI126614	93.855	-	53,013	53,013
NIH	Allergy, Immunology and Transplantation Research		Impact of the Initial Influenz		Emory University		U01AI144673	93.855	1,149,783	3,676,180	4,894,794
					University of Cincinnati				68,831	-	-
NIH	Allergy, Immunology and Transplantation Research		SEAL (Stopping Atopic dermatit	Harvard College		113159-5132934	U01AI147462	93.855	-	429,902	429,902
NIH	Allergy, Immunology and Transplantation Research		Dynamic regulatory network mod	University of California, Irvine		2023-1986	U01AI150748	93.855	-	326,393	326,393
NIH	Allergy, Immunology and Transplantation Research		Atopic dermatitic mechanisms				U01AI152034	93.855	-	223,124	223,124
NIH	Allergy, Immunology and Transplantation Research		Randomized trial of viral spec		Seattle Children's Hospital		U01AI157620	93.855	222,869	599,496	822,365
NIH	Allergy, Immunology and Transplantation Research		Multi-omics of the Frequent Ex				U01AI159087	93.855	-	103,504	103,504
NIH	Allergy, Immunology and Transplantation Research		Advancing Transplantation Outc	Harvard Medical School		GENFD0002098919/U01AI1630	U01AI163072	93.855	-	2,169	2,169
NIH	Allergy, Immunology and Transplantation Research		Itacimib to reduce lung infl	Duke University		A03-5348/U01AI163099-01	U01AI163099	93.855	-	90,044	90,044
NIH	Allergy, Immunology and Transplantation Research		Comparison of High versus Stan	Vanderbilt University Medical Center		VUMC114005	U01AI167799	93.855	-	153,892	153,892
NIH	Allergy, Immunology and Transplantation Research		HiPC-III ImmuneSignatures IOF	La Jolla Institute for Immunology		20012-01-156-284	U01AI167892	93.855	-	173,917	173,917
NIH	Allergy, Immunology and Transplantation Research		SPR400079: Park Extension GENFD0002585825 SPR400079 07/08/2024 (version 0)	Children's Hospital Boston		GENFD0002585825	U01AI179563	93.855	-	140,230	140,230
NIH	Allergy, Immunology and Transplantation Research		Consortium of Food Allergy Res				U01AI181966	93.855	-	369,385	369,385
NIH	Allergy, Immunology and Transplantation Research		SPR202434: Epithelial Genes in Allergic Inflammation-Renewal 09/01/2021 (version 0)				U19AI070235	93.855	-	1,360,882	1,360,882
NIH	Allergy, Immunology and Transplantation Research		Systems Biological Assessment	Stanford University Medical Center		62927133-229950	U19AI167903	93.855	-	64,371	64,371
NIH	Allergy, Immunology and Transplantation Research		i-AKC: Integrated AIRR Knowled	University of Texas at Dallas		GMO240908 PO000003119	U24AI177622	93.855	-	55,616	55,616
NIH	Allergy, Immunology and Transplantation Research		SPR400067: CADRE- Wisconsin Sub-in 000003865 SPR400067 08/06/2024 (version 0)	Univ of Wisconsin		3865	U24AI179612	93.855	-	17,667	17,667
NIH	Allergy, Immunology and Transplantation Research		Consortium of Eosinophilic Gas		Ann & Robert H Lurie Children's Hospital		U54AI117804	93.855	17,465	342,814	1,120,871
					Arkansas Children's Hospital				15,550	-	-
					Baylor College of Medicine				7,165	-	-
					Children's Hospital of Philadelphia				47,918	-	-
					ICAHN School of Medicine at Mount Sinai				117,999	-	-
					Mayo Clinic Arizona				33,885	-	-
					Northwestern University				95,015	-	-
					Research Inst. at Nationwide Hos				31,378	-	-

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
					Univ of Pennsylvania				\$ 126,954	\$ -	\$ -
					University of Alabama at Birmingham				28,348	-	-
					University of Colorado				54,066	-	-
					University of North Carolina-Chapel Hill				139,590	-	-
					University of Utah				32,731	-	-
					Vanderbilt University Medical Center				20,974	-	-
					Wake Forest Univ School of Medicine				9,019	-	-
NIH	Allergy, Immunology and Transplantation Research		SPR202062: 6/19/20 CAUSE UAH159087A SPR202062 04/09/2021 (version 0)					93.855	-	325,215	325,215
NIH	Allergy, Immunology and Transplantation Research		Vaccine and Treatment Evaluati		Henry M. Jackson Foundation for the			93.855	96,565	1,509,124	1,646,063
					Nationwide Childrens Hospital				14,513	-	-
					University of Cincinnati				25,861	-	-
NIH	Allergy, Immunology and Transplantation Research		Leadership Group for an Infect	Emory University		UM1A148684	UM1A148684	93.855	-	63,892	63,892
NIH	Allergy, Immunology and Transplantation Research		Deciphering the spatial relati	Infectious Diseases Clinical Researc Co		A927120	UM1A148684	93.855	-	65,839	65,839
NIH	Allergy, Immunology and Transplantation Research		ADRN - LEADS: Longitudinal End	National Jewish Health		20123803-CCHMC	UM1A151958	93.855	-	272,024	272,024
NIH	Allergy, Immunology and Transplantation Research		Childhood Asthma in Urban Sett	Univ of Wisconsin		1464	UM1A1160040	93.855	-	569,254	569,254
NIH	Allergy, Immunology and Transplantation Research		SPR400254: SUNBEAM Subaward 2024-2031 2006518067 SPR400254 04/04/2024 (version 0)	Johns Hopkins School of Medicine		2006518067	UM1A1182034	93.855	-	708,374	708,374
CDC	Allergy, Immunology and Transplantation Research		Safety of simultaneous mRNA CO			200-2012-53661	200-2012-53661/75D30122FO	93.RD	-	382,396	382,396
CDC	Allergy, Immunology and Transplantation Research		Development, validation and us	University of Cincinnati		015548-00002:		93.RD	-	11,016	11,016
CDC	Allergy, Immunology and Transplantation Research		Respiratory Virus Surveillance	Children's Hospital Boston		GENFD0002272664	75D30122C13330	93.RD	-	97,964	97,964
CDC	Allergy, Immunology and Transplantation Research		CLINICAL IMMUNIZATION SAFETY A			75D30123D18246	75D30123D18246	93.RD	-	173,035	173,035
CDC	Allergy, Immunology and Transplantation Research		CISA CLINICAL IMMUNIZATION SAF			75D30123F00002	75D30123F00002	93.RD	-	187,212	187,212
CDC	Allergy, Immunology and Transplantation Research		SPR400186: Xiao NCI SBIR 2023 75N91024C00084 SPR400186 09/16/2024 (version 0)	Tetraimaging LLC		75N91024C00084	75N91024C00084	93.RD	-	12,359	12,359
NIH	Allergy, Immunology and Transplantation Research		A Molecular Atlas for Benchmar	Stanford University Medical Center		63008243-240857	75N93022C00052	93.RD	-	181,534	181,534
NIH	Allergy, Immunology and Transplantation Research		SPR201018: RTOP FY2020.A1B1CID10123 HHSN2722013000161 SPR2010 07/12/2019 (version 0)		Pennington Biomedical Research Center		HHSN2722013000161	93.RD	-	119,550	119,550
NIH	Allergy, Immunology and Transplantation Research		Mouse and Guinea Pig Models f				HHSN272201700017U75N9302	93.RD	41,351	162,145	203,496
NIH	Allergy, Immunology and Transplantation Research		Pharmacokinetics of Understud	Duke University		252507	HHSN2752018000031	93.RD	-	10,486	10,486
NIH	Allergy, Immunology and Transplantation Research		Pharmacokinetics, Pharmacodyn	Duke University		278589	HHSN2752018000031	93.RD	-	17,283	17,283
	Allergy, Immunology and Transplantation Research Total								4,808,810	25,385,499	30,194,309
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Vega K23 - Resubmission - 1				K23AR081424	93.846	-	155,324	155,324
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Cincinnati Rheumatic Diseases				P30AR070549	93.846	-	813,149	813,149
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Pediatric musculoskeletal and				P30AR076316	93.846	-	38,881	38,881
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Deciphering mechanisms of myob				R01AR068286	93.846	-	473,794	473,794
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Multi-site Randomized Clinical Trial of FIT Teens for Ju	Emory University			R01AR070474	93.846	9,181	5,167	14,348
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Transcription Factor Genetics				R01AR073228	93.846	-	160,539	160,539
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Identifying neural pathophysio		Universitat De Barcelona		R01AR074795	93.846	4,677	36,274	40,951
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Epigenetic Determinants Influe		Children's Hospital of Philadelphia		R01AR075857	93.846	4,434	238,622	245,890
					Duke University				1,391	-	-
					Johns Hopkins University				973	-	-
					Stanford University				470	-	-
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		The Pediatric Lupus Nephritis		Ann & Robert H Lurie Children's Hospital		R01AR079124	93.846	5,106	586,325	623,920
					Baylor College of Medicine.				7,405	-	-
					Medical College of Wisconsin				2,264	-	-
					Nationwide Childrens Hospital				240	-	-
					Seattle Children's Hospital				4,388	-	-
					University of North Carolina-Chapel Hill				12,192	-	-
					University of Utah				3,000	-	-
					Washington University				3,000	-	-
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Pathogenesis of Systemic Juven				R01AR079524	93.846	-	506,210	506,210
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Development and optimization o				R01AR083368	93.846	-	326,556	326,556
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Natural history and validation				R01AR084717	93.846	-	39,252	39,252
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Development of Foundational Co	Children's Hospital Boston		GENFD0002512074	R21AR084034	93.846	-	15,816	15,816
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Improving delivery of therapeu				R33AR076771	93.846	-	62	62
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Electrical Coupling of Circula				R33AR078060	93.846	-	178,389	178,389
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Cincinnati Training Program in				T32AR069512	93.846	-	48,949	48,949
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		SPR202315: Grom Renewed T32 TAR069512B SPR202315 05/01/2020 (version 0)				TAR069512B	93.846	-	198,306	198,306
NIH	Arthritis, Musculoskeletal and Skin Diseases Research		Towards personalized use of me	Oklahoma Medical Research Foundation		0352-02_CHMC_SH	UC2AR081032	93.846	-	195,498	195,498
	Arthritis, Musculoskeletal and Skin Diseases Research Total								58,721	4,017,113	4,075,834
CDC	Assistance Programs for Chronic Disease Prevention and Control		SPR400160: DICAYA_Mendoza Sub to IU_11.8.24 5 U18DP006500-05 09/30/2024 (version 0)	Indiana University		5 U18DP006500-05-00	U18DP006500	93.945	-	34,488	34,488
	Assistance Programs for Chronic Disease Prevention and Control Total								-	34,488	34,488
NIH	Biomedical Research and Research Training		Mechanisms of cardiomyocyte dy				K08GM148957	93.859	-	199,837	199,837
NIH	Biomedical Research and Research Training		Developing a Precision Medicin				K23GM151444	93.859	-	185,482	185,482
NIH	Biomedical Research and Research Training		Mechanisms of Homodomain Tran	University of Cincinnati			R01GM079428	93.859	23,967	134,217	158,184
NIH	Biomedical Research and Research Training		Dynamic regulation of lineage				R01GM143161	93.859	-	364,955	364,955
NIH	Biomedical Research and Research Training		Therapeutic resistance and agg	University of Cincinnati		014895-00002	R01GM144426	93.859	-	21,103	21,103
NIH	Biomedical Research and Research Training		Finding Appropriate Subtypes i	Children's Hospital of Philadelphia		FAST BOLLUS	R01GM145698	93.859	-	136,027	136,027
NIH	Biomedical Research and Research Training		Establishment of a multi-cente				R01GM150093	93.859	-	158,319	158,319
NIH	Biomedical Research and Research Training		Leveraging multi-omics to maxi	Ann & Robert H Lurie Children's Hospital			R21GM151703	93.859	18,846	149,401	168,247
NIH	Biomedical Research and Research Training		Biobank of small extracellular				R21GM151734	93.859	-	230,674	230,674
NIH	Biomedical Research and Research Training		WE ENGAGE via Data and Stories to Improve Community Health				R25GM129808	93.859	-	6,968	6,968
NIH	Biomedical Research and Research Training		#MyHealth: Training the Next G	University of Michigan		SUBK00013637	R25GM137361	93.859	-	29,763	29,763
NIH	Biomedical Research and Research Training		Regulatory Mechanisms Governin				R35GM140805	93.859	-	418	418
NIH	Biomedical Research and Research Training		How CHAF1B maintains cell stat				R35GM142452	93.859	-	377,954	377,954
NIH	Biomedical Research and Research Training		Antibiotic Model-Informed Prec				R35GM146701	93.859	-	437,402	437,402

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
	NIH	Biomedical Research and Research Training	Novel regulators of macrophage	University of Cincinnati		015245-0002	R35GM149538	93.859	\$ -	\$ 16,727	\$ 16,727
	NIH	Biomedical Research and Research Training	Mechanisms regulating the bios				R35GM150691	93.859	-	499,756	499,756
	NIH	Biomedical Research and Research Training	Structure and function of stap				R35GM151986	93.859	-	301,408	301,408
	NIH	Biomedical Research and Research Training	Translational approaches to un				R35GM155165	93.859	-	463,386	463,386
	NIH	Biomedical Research and Research Training	SPR400188: Mikedis R35 2-1-24 1R35GM156830-01 SPR400188 01/20/2025 (version 0)				R35GM156830	93.859	-	102,394	102,394
		Biomedical Research and Research Training Total							42,813	3,816,191	3,859,004
	NIH	Blood Diseases and Resources Research	Sickle Cell Anemia, Splenic Pa		Bugando Medical Centre		K23HL153763	93.839	9,750	162,679	172,429
	NIH	Blood Diseases and Resources Research	SPR400098: Zheng PPG transfer to Brigham 131490 SPR400098 08/01/2024 (version 0)	Brigham & Women's Hospital			131490 P01HL158688	93.839	-	446,172	446,172
	NIH	Blood Diseases and Resources Research	Mechanisms of granulocyte home		Imperial College of Science Technology		R01HL122661	93.839	29,989	137,589	167,578
	NIH	Blood Diseases and Resources Research	Linking Endotypes and Outcomes	Children's Hospital of Philadelphia			3201710624 R01HL148054	93.839	-	45	45
	NIH	Blood Diseases and Resources Research	The role of mitochondria in he		Johns Hopkins University		R01HL151654	93.839	21,115	212,532	233,647
	NIH	Blood Diseases and Resources Research	The Role of Erythroblastic Id				R01HL152099	93.839	-	85,772	85,772
	NIH	Blood Diseases and Resources Research	Spatial control of myeloid dif				R01HL153229	93.839	-	298,380	298,380
	NIH	Blood Diseases and Resources Research	MIDAS: Microangiopathy, Endoth	The Ohio State University Research Fnd			60078812 R01HL153723	93.839	-	100,568	100,568
	NIH	Blood Diseases and Resources Research	Inflammatory Mechanisms in Pos	University of Cincinnati			014082-0002 R01HL155579	93.839	-	19,502	19,502
	NIH	Blood Diseases and Resources Research	Transfusion and Organ Dysfunct	Nationwide Children's Hospital			700277-0223-00 R01HL157208	93.839	-	91,722	91,722
	NIH	Blood Diseases and Resources Research	Role of the local vascular mic				R01HL158616	93.839	-	197,296	197,296
	NIH	Blood Diseases and Resources Research	The role of contact pathway fa				R01HL160582	93.839	-	536,138	536,138
	NIH	Blood Diseases and Resources Research	Thrombosis Risk in Transgender				R01HL161153	93.839	-	629,082	629,082
	NIH	Blood Diseases and Resources Research	Hematopoietic Stem Cell engraf				R01HL162649	93.839	-	337,558	337,558
	NIH	Blood Diseases and Resources Research	The Darbepoetin Kindergarten D	RTI International			3-312-0219253-67538L R01HL166254	93.839	-	179,119	179,119
	NIH	Blood Diseases and Resources Research	Preserving the bone marrow nic	University of Florida			SUB00003942 R01HL166512	93.839	-	138,687	138,687
	NIH	Blood Diseases and Resources Research	Regulatory mechanisms of hemat		University of Colorado		R01HL167731	93.839	18,277	736,393	754,670
	NIH	Blood Diseases and Resources Research	Allogeneic virus-specific T-ce		Children's National Medical Center		R01HL169242	93.839	47,255	279,452	326,707
					University of Cincinnati				30,900	-	30,900
	NIH	Blood Diseases and Resources Research	Initiators of thrombotic micro		Children's Hospital of Philadelphia		R01HL171046	93.839	134,534	354,380	488,914
					University of Cincinnati				183,216	-	183,216
	NIH	Blood Diseases and Resources Research	Decoding innate immune signali				R35HL166430	93.839	-	883,264	883,264
	NIH	Blood Diseases and Resources Research	SPR400154: Lucas NIH R35 Feb 2024 R35HL177125 SPR400154 01/01/2025 (version 0)				R35HL177125	93.839	-	517,519	517,519
	NIH	Blood Diseases and Resources Research	Rho GTPase inhibitor for refri	Orange Grove Bio LLC			SBIR_OGB4_Zheng_Y	93.839	-	115,953	115,953
	NIH	Blood Diseases and Resources Research	Decoding the Paradox of DDX41-				R56HL169244	93.839	-	135,058	135,058
	NIH	Blood Diseases and Resources Research	SPR400187: Zheng SBIR Mogling R43 HL172285-01A1 SBIR_MoglingB 09/23/2024 (version 0)	Mogling Bio Inc			RHL172285	93.839	-	65,946	65,946
	NIH	Blood Diseases and Resources Research	Realizing Effectiveness Across		Bayler College of Medicine.		U01HL133883	93.839	12,063	918,678	930,741
					CEFA Centre Hospitalier Monkole		U01HL133883	93.839	56,581	-	56,581
					Hospital Pediatrico David Bernardino		U01HL133883	93.839	106,186	-	106,186
					Mhale Regional Referral Hospital		U01HL133883	93.839	140,293	-	140,293
					The Chancellor, Masters and Scholars		U01HL133883	93.839	99,574	-	99,574
					The Feinstein Institute Medical Research		U01HL133883	93.839	17,382	-	17,382
					University Health Network		U01HL133883	93.839	19,975	-	19,975
	NIH	Blood Diseases and Resources Research	Sickle Cell Improvement: ENhan	The Nemours Foundation			PO010597 U01HL159850	93.839	-	157,778	157,778
		Blood Diseases and Resources Research Total							927,090	7,737,262	8,664,352
	NIH	Cancer Biology Research	The role of transcription elon				R01CA234038	93.396	-	41,789	41,789
	NIH	Cancer Biology Research	New activities of the human DE		University of Kentucky Research Fnd		R01CA239605	93.396	56,969	147,474	204,443
	NIH	Cancer Biology Research	Defining genetic and metabolic	University of Cincinnati			012828-002 R01CA239697	93.396	-	124,856	124,856
	NIH	Cancer Biology Research	Patho-Genetic Analysis of Inva		Massachusetts General Hospital.		R01CA240317	93.396	67,030	208,094	275,124
					University of Utah				170,220	-	170,220
	NIH	Cancer Biology Research	Modeling myelodysplasia		Johns Hopkins University		R01CA253981	93.396	32,146	218,964	251,110
					Yale University - Grants				209,806	-	209,806
	NIH	Cancer Biology Research	Dissecting innate immune signa		New York University School of Medicine		R01CA271455	93.396	303,685	305,370	609,055
	NIH	Cancer Biology Research	Mechanisms underlying gastric				R01CA272903	93.396	-	372,198	372,198
	NIH	Cancer Biology Research	The role of DNAB1-PKA-β-cate				R01CA278834	93.396	-	650,667	650,667
	NIH	Cancer Biology Research	HPV and host factors in juveni				R01CA287486	93.396	-	409,196	409,196
	NIH	Cancer Biology Research	SPR400302: 06.14.24-R21-Salomonis R21CA300922 SPR400302 04/01/2025 (version 0)				R21CA300922	93.396	-	38,358	38,358
	NIH	Cancer Biology Research	Mechanisms coupling DEK to onc				R37CA218072	93.396	-	294,170	294,170
	NIH	Cancer Biology Research	Pathogenic Role of Foxl1+ Hepa				R37CA225807	93.396	-	266,790	266,790
	NIH	Cancer Biology Research	SPR400035: Jones City of Hope-NIH R01 Sep 2023 66246.2013377 06/14/2024 (version 0)	City of Hope			66246.2013377.669301 R37CA292678	93.396	-	15,290	15,290
	NIH	Cancer Biology Research	Therapeutic insights through p				R50CA211404	93.396	-	209,850	209,850
	NIH	Cancer Biology Research	Understanding the immune respo	Washington University			WU-24-0236 U01CA275304	93.396	-	53,237	53,237
		Cancer Biology Research Total							839,856	3,356,303	4,196,159
	NIH	Cancer Cause and Prevention Research	Research Into Visual Endpoints	Vanderbilt University Medical Center			VUMV67585 R01CA225005	93.393	-	258	258
	NIH	Cancer Cause and Prevention Research	Investigating facilitator-driv	The University of Texas at Austin			UT AUS-SUB00001294 R01CA272757	93.393	-	833	833
	NIH	Cancer Cause and Prevention Research	Towards an inclusive genomie r	Ohio State University Comprehensive Cane			SPC-1000012951 GR133524 R01CA284595	93.393	-	380,499	380,499
	NIH	Cancer Cause and Prevention Research	A novel algorithm to compute a				R21CA263704	93.393	-	49,794	49,794
	NIH	Cancer Cause and Prevention Research	A Pilot Feasibility Trial of a		Seattle Children's Hospital		R21CA268945	93.393	15,334	64,508	79,842
					St Jude Children's Research Hospital				15,215	-	15,215
		Cancer Cause and Prevention Research Total							30,549	495,892	526,441
	NIH	Cancer Detection and Diagnosis Research	SPR400331: Hu sub with Kotagiri at UC (NIH) - Resubmission - 09/17/2024 (version 0)	University of Cincinnati			016399-0002 R01CA279962	93.394	-	11,336	11,336
		Cancer Detection and Diagnosis Research Total							-	11,336	11,336
	NIH	Cancer Research Manpower	The role of ERBB2 signaling in				F32CA290798	93.398	-	95,934	95,934
	NIH	Cancer Research Manpower	Targeting MBNL1-mediated alter				K08CA237753	93.398	-	174,570	174,570
	NIH	Cancer Research Manpower	Kinase-independent mechanism o				K08CA270305	93.398	-	246,759	246,759
	NIH	Cancer Research Manpower	Dissecting the role of clonal				R00CA252005	93.398	-	326,061	326,061
	NIH	Cancer Research Manpower	SPR400041: Drucker T32 1020950 SPR400041 06/28/2024 (version 0)	University of Cincinnati			1020950 T32CA236764	93.398	-	83,205	83,205
		Cancer Research Manpower Total							-	926,529	926,529

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
	NIH	Cancer Treatment Research	(PQ10) Role of Gut Microbiota	The University of Texas Southwestern		PO: 00001910A GMO 201112	R01CA231303	93.395	\$ -	\$ 8,493	\$ 8,493
	NIH	Cancer Treatment Research	Targeted Inhibition in Leukemi				R01CA237016	93.395	-	116,824	116,824
	NIH	Cancer Treatment Research	Co-targeting S6 and TAM Kinase	University of Cincinnati		12653-002	R01CA239657	93.395	-	455	455
	NIH	Cancer Treatment Research	SPR201492: Azam NIH 12 2019 [R01CA250516] SPR201492 07/01/2020 (version 0)				R01CA250516	93.395	-	202,252	202,252
	NIH	Cancer Treatment Research	Therapeutic resistance and agg	University of Cincinnati		013734-00002	R01CA255331	93.395	-	1,580	1,580
	NIH	Cancer Treatment Research	Therapeutic targeting of IRAK4	Albert Einstein College of Medicine			R01CA275007	93.395	-	233,454	233,454
	NIH	Cancer Treatment Research	Rational targeting of Cdc42 to				R01CA278756	93.395	-	608,788	608,788
	NIH	Cancer Treatment Research	SPR400107: Lu NIH Feb 2024 R01NS140460 SPR400107 12/01/2024 (version 0)				R01NS140460	93.395	-	103,308	103,308
	NIH	Cancer Treatment Research	SPR300602: Azam R21 MPN Duap1 [R21CA280723] SPR300602 04/01/2023 (version 0)				R21CA280723	93.395	-	54,420	54,420
	NIH	Cancer Treatment Research	SPR400314: Malik NIH R21 June 2024 R21CA299166 SPR400314 04/01/2025 (version 0)				R21CA299166	93.395	-	16,426	16,426
	NIH	Cancer Treatment Research	SPR300995: Pommett CHLA-TACL T2020-004 [T2020-004] SPR300995 11/01/2023 (version 0)	Children's Hospital Los Angeles		T2020-004	R37CA266550	93.395	-	344	344
	NIH	Cancer Treatment Research	The Pediatric Brain Tumor Cons	St. Jude's Children's Hospital		110068210-7947557	U01CA081457	93.395	-	46,866	46,866
	NIH	Cancer Treatment Research	SPR400296: Wells NIH U01 April 2024 U01CA298630 SPR400296 04/01/2025 (version 0)				U01CA298630	93.395	-	20,900	20,900
	NIH	Cancer Treatment Research	Norris PHH-COG Associate Medic	Public Health Institute		AR03186	U10CA180886	93.395	-	48,597	48,597
	NIH	Cancer Treatment Research	COMMITTEE LEADERSHIP: NIH Nati	Public Health Institute		AR03217	U10CA180886	93.395	-	22,023	22,023
	NIH	Cancer Treatment Research	Study Chair	Public Health Institute		AR03413	U10CA180886	93.395	-	10,188	10,188
	NIH	Cancer Treatment Research	SPR202548: Geller PHH-COG Study Chair 2021 AR03426 SPR202548 03/01/2021 (version 0)			AR03426	U10CA180886	93.395	-	7,093	7,093
	NIH	Cancer Treatment Research	SPR202545: Geller PHH-COG Study Chair AREN1921 2021 AR03451 S 03/01/2021 (version 0)			AR03451	U10CA180886	93.395	-	3,538	3,538
	NIH	Cancer Treatment Research	COG NCTN Network Group Operati	Public Health Institute		AR04476	U10CA180886	93.395	-	7,278	7,278
	NIH	Cancer Treatment Research	SPR202790: AHEP 1531 AR04543U10CA180886 SPR202790 03/01/2021 (version 0)			AR04543	U10CA180886	93.395	-	23,996	23,996
	NIH	Cancer Treatment Research	COG NCTN Network Group Operati	Public Health Institute		AR04575	U10CA180886	93.395	-	3,427	3,427
	NIH	Cancer Treatment Research	Biomarker, Imaging and Quality	Public Health Institute		AR04810	U10CA180886	93.395	-	8,079	8,079
	NIH	Cancer Treatment Research	COG Renal Tumor Committee Lead	Public Health Institute		AR10915	U10CA180886	93.395	-	21,476	21,476
	NIH	Cancer Treatment Research	SPR300872: Breese PHH-COG Study Chair AALL2321 AR66192 SPR300 03/01/2023 (version 0)			AR66192	U10CA180886	93.395	-	3,845	3,845
	NIH	Cancer Treatment Research	SPR300931: Norris PHH-COG BIQSP AHOD2131 [AR67052] SPR300931 03/01/2023 (version 0)			AR67052	U10CA180886	93.395	-	819	819
	NIH	Cancer Treatment Research	PHH-COG PCR Work Order 2021	Public Health Institute		Norris_R_PHH/NIH	U10CA180886	93.395	-	9,190	9,190
	NIH	Cancer Treatment Research	PHH-COG NCTN Work Order 2021	Public Health Institute		U10CA180886	U10CA180886	93.395	-	34,332	34,332
	NIH	Cancer Treatment Research	SPR201196: Tao COG from CHOP U10CA180886 SPR201196 05/24/2019 (version 0)			U10CA180886	U10CA180886	93.395	-	8,467	8,467
	NIH	Cancer Treatment Research	Childhood Cancer Survivor Stud	St. Jude's Children's Hospital		RFA-CA-20-052	U24CA055727	93.395	-	72,177	72,177
	NIH	Cancer Treatment Research	SPR300855: Pfallay-Smiley PBTC-N14 [PBTC-N14] SPR300855 07/31/2023 (version 0)			PBTC-N14	UM1CA081457	93.395	-	48	48
	NIH	Cancer Treatment Research	Norris PHH-COG PEP-CTN WLI Cor	Public Health Institute		AR06748	UM1CA228823	93.395	-	4,810	4,810
	NIH	Cancer Treatment Research	SPR400204: Pressy PHH-COG PEP-CTN Work Order AR75650 SPR4002 08/01/2024 (version 0)			AR75650	UM1CA228823	93.395	-	6,604	6,604
	NIH	Cancer Treatment Research	SPR400286: Pressy PHH-COG PEP-CTN WLI Work Order AR76622 SPR 08/01/2024 (version 0)			AR76622	UM1CA228823	93.395	-	13,746	13,746
		Cancer Treatment Research Total							-	1,723,843	1,723,843
	NIH	Cardiovascular Diseases Research	SPR400008: Keira Hassel F30 - Resubmission - 1 F30HL172585 SP 08/28/2024 (version 0)				F30HL172585	93.837	-	22,874	22,874
	NIH	Cardiovascular Diseases Research	GDF10 in Neonatal Heart Develo				F31HL168819	93.837	-	42,434	42,434
	NIH	Cardiovascular Diseases Research	Effects of early Retinoic Acid				F31HL172346	93.837	-	37,735	37,735
	NIH	Cardiovascular Diseases Research	SPR300956: Ta Sub to Cleveland Clinic Children's 2023 [CCT235 08/23/2022 (version 0)	Cleveland Clinic Foundation		CCF23596583	K23HL150279	93.837	-	4,997	4,997
	NIH	Cardiovascular Diseases Research	Mouse Cardiac Physiology and S	The University of Texas Southwestern		GMO241018	P01HL160488	93.837	-	464,420	464,420
	NIH	Cardiovascular Diseases Research	Thrombospondin 4 regulates ada				R01HL105924	93.837	-	803,489	803,489
	NIH	Cardiovascular Diseases Research	Venous Malformations (VM): A M				R01HL117952	93.837	-	637,366	637,366
	NIH	Cardiovascular Diseases Research	Using MRI to visualize regiona	Duke University	University of Cincinnati	A034671	R01HL126771	93.837	6,173	131,742	137,915
	NIH	Cardiovascular Diseases Research	Molecular examination of mitoc		Univ of Calif-Davis-Mmrc		R01HL132831	93.837	279,964	-	279,964
	NIH	Cardiovascular Diseases Research	Molecular mechanisms of atrial				R01HL137766	93.837	-	403,030	403,030
	NIH	Cardiovascular Diseases Research	Predictive Molecular Markers o				R01HL142210	93.837	-	144,622	144,622
	NIH	Cardiovascular Diseases Research	Cardiac Fibroblasts in Postnat				R01HL142217	93.837	-	674,249	674,249
	NIH	Cardiovascular Diseases Research	MRI Phenotyping of Early BPD a				R01HL146689	93.837	-	33,030	33,030
	NIH	Cardiovascular Diseases Research	Impact of Well-Timed vs. Mis-t		Rush University Medical Center		R01HL147915	93.837	35,502	571,994	607,496
	NIH	Cardiovascular Diseases Research	Novel Methods to Grow the Impa				R01HL147957	93.837	-	77,403	77,403
	NIH	Cardiovascular Diseases Research	Accelerating research to advan		Vanderbilt University Medical Center		R01HL151604	93.837	11,705	12,431	24,136
	NIH	Cardiovascular Diseases Research	Mechanisms underlying myotomo				R01HL154522	93.837	-	517,864	517,864
	NIH	Cardiovascular Diseases Research	Hypertrophic Cardiomyopathy: U	Brigham & Women's Hospital		2020A015252	R01HL155568	93.837	-	3,867	3,867
	NIH	Cardiovascular Diseases Research	Endothelial subpopulations in				R01HL156270	93.837	-	375,423	375,423
	NIH	Cardiovascular Diseases Research	Coronary Atherosclerosis and I	University of Cincinnati		014604-00002	R01HL156779	93.837	-	93,535	93,535
	NIH	Cardiovascular Diseases Research	Innate immune response signali				R01HL156852	93.837	-	641,268	641,268
	NIH	Cardiovascular Diseases Research	Pathogenesis and Treatment of				R01HL156866	93.837	-	593,001	593,001
	NIH	Cardiovascular Diseases Research	Lipoprotein Interactions in th		University of Cincinnati		R01HL157260	93.837	109,296	360,743	470,039
	NIH	Cardiovascular Diseases Research	Effect of reproductive history		Kaiser Foundation Res Institute		R01HL158100	93.837	2,836	797,481	898,586
					University of Cincinnati			86,324	-	-	-
					University of Pittsburgh			11,945	-	-	-
	NIH	Cardiovascular Diseases Research	Microprotein Regulation of Mit				R01HL160569	93.837	-	283,689	283,689
	NIH	Cardiovascular Diseases Research	Dissecting the role of the car				R01HL160765	93.837	-	571,589	571,589
	NIH	Cardiovascular Diseases Research	Thrombospondin1-regulated atro				R01HL162595	93.837	-	774,300	774,300
	NIH	Cardiovascular Diseases Research	SPR400255: Search CVD Univ of Colorado FY25.253.005 SPR40025 09/01/2024 (version 0)	University of Colorado Denver		FY25.253.005	R01HL162810	93.837	-	117,190	117,190
	NIH	Cardiovascular Diseases Research	Kids: Nocturnal Investigation	Feinstein Institute for Medical Research		AWD00001721_CR_Cincinnati	R01HL162912	93.837	-	30,574	30,574
	NIH	Cardiovascular Diseases Research	Role of SHE and ABL signaling	University of Florida		6145-1033-00-A	R01HL163161	93.837	-	67,144	67,144
	NIH	Cardiovascular Diseases Research	SPR301319: CTA - G1AA - Genetics in Atrial Arrhythmias [A23-0 07/01/2023 (version 0)	Lurie Children's Hospital of Chicago		A23-0094-S005	R01HL164773	93.837	-	377	377
	NIH	Cardiovascular Diseases Research	Racial/Ethnic Influences on Ea	Univ of California		2022-1735	R01HL164823	93.837	-	30,533	30,533
	NIH	Cardiovascular Diseases Research	Harnessing novel glucocorticoi				R01HL166356	93.837	-	346,592	346,592
	NIH	Cardiovascular Diseases Research	Role of apoE in HDL-mediated e		University of Cincinnati		R01HL167200	93.837	78,266	503,775	582,041
	NIH	Cardiovascular Diseases Research	Pathogenesis of Vascular Anoma		University of Cincinnati		R01HL167700	93.837	25,634	518,120	543,754
	NIH	Cardiovascular Diseases Research	Mechanisms governing the diffu				R01HL168790	93.837	-	462,207	462,207
	NIH	Cardiovascular Diseases Research	Developing DWORF gene therapy				R01HL171221	93.837	-	639,438	639,438
	NIH	Cardiovascular Diseases Research	SPR400148: Acetylation Regulates YAP Subcellular Localization 01/01/2025 (version 0)				R01HL172839	93.837	-	153,264	153,264
	NIH	Cardiovascular Diseases Research	SPR400211: Xu - Cellular determinants of responsiveness to mT 02/01/2025 (version 0)				R01HL172914	93.837	-	121,767	121,767
	NIH	Cardiovascular Diseases Research	Finding the contribution of th				R21HL162572	93.837	-	888	888
	NIH	Cardiovascular Diseases Research	Patient centered outcome measu	University of Cincinnati		015733-00002	R21HL172156	93.837	-	53,773	53,773
	NIH	Cardiovascular Diseases Research	Intramuscular vs. Enteral Penai		Children's Research Institute		R33HL166441	93.837	258,547	306,787	1,761,806
					Murdoch Childrens Research Institute			106,841	-	-	-
					The University of Melbourne			11,219	-	-	-

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
					Uganda Heart Institute				\$ 953,586	\$ -	\$ -
					University of Washington				124,826	-	-
	NIH	Cardiovascular Diseases Research	Understanding Cardiovascular D			T32HL125204		93.837	-	213,894	213,894
	NIH	Cardiovascular Diseases Research	Administrative Coordinating Ce		Children's Hospital Boston	U01HL131003		93.837	432,210	5,102,818	7,027,982
					Children's Hospital Los Angeles				40,000	-	-
					Children's Hospital of Philadelphia				129,573	-	-
					Columbia University				316,536	-	-
					Emory University				65,955	-	-
					Harvard College				4,984	-	-
					ICAHN School of Medicine at Mount Sinai				259,127	-	-
					Mohammed Bin Rashid University				68,150	-	-
					The Catholic University of America				15,830	-	-
					The University of Texas Science Center				31,664	-	-
					Univ of Michigan				98,028	-	-
					University of Pittsburgh				40,841	-	-
					University of Utah				216,050	-	-
					Yale University				206,216	-	-
	NIH	Cardiovascular Diseases Research	SPR115933: Long-term Outcomes of Children with Hypoplastic Le 03/31/2014 (version 0)	New England Research Institutes		U10HL109673	U10HL109673	93.837	-	1,351	1,351
	NIH	Cardiovascular Diseases Research	Single Institutional Review Bo	New England Research Institutes		NERI_Cnota, James	U24HL135691	93.837	-	144,991	144,991
	NIH	Cardiovascular Diseases Research	SPR400336: Lorts - Stanford - PKN3 - July 8, 2024 63577550-22 02/01/2024 (version 0)	Stanford University		63577550-224250	UG3HL163311	93.837	-	1,131	1,131
	NIH	Cardiovascular Diseases Research	Pediatric Influence of Cooling	University of Michigan		SUBK00017613	UH3HL159134	93.837	-	11,488	11,488
	NIH	Cardiovascular Diseases Research	Pediatric Heart Network Joint		University of Kentucky Research Fnd		UM1HL172717	93.837	80,109	253,143	333,252
	NIH	Cardiovascular Diseases Research	SPR301248: Tourdet NIH-BCC May 2024 10010.010.011 SPR301248 01/03/2024 (version 0)	Black Canyon Consulting, LLC.		10010.010.011		93.RD	-	16,894	16,894
	NIH	Cardiovascular Diseases Research	SPR400060: Towbin_Sub_2_Chicago SUB00001217 SPR400060 01/01/2024 (version 0)	University of Chicago		SUB00001217		93.RD	-	7,953	7,953
			Cardiovascular Diseases Research Total						4,107,937	18,180,668	22,288,605
	NIH	Child Health and Human Development Extramural Research	SPR301429: Sheak - The Interaction of Perinatal Lung Injury a 07/01/2024 (version 0)	Weill Cornell Medical College		241381-5	K12HD000850	93.865	-	55,968	55,968
	NIH	Child Health and Human Development Extramural Research	Child Health Research Career D				K12HD028827	93.865	-	250,335	250,335
	NIH	Child Health and Human Development Extramural Research	Clinical Pharmacology K12 Trai		Midwestern University		K12HD113190	93.865	102,753	126,851	239,644
					University of Colorado				10,040	-	-
	NIH	Child Health and Human Development Extramural Research	SPR400023: Real K18 VR Firearm K18HD117377 SPR400023 09/19/2024 (version 0)				K18HD117377	93.865	-	187,124	187,124
	NIH	Child Health and Human Development Extramural Research	Electrophysiological Biomarker				K23HD101416	93.865	-	65,383	65,383
	NIH	Child Health and Human Development Extramural Research	Tracking early emergence of so				K23HD109375	93.865	-	163,384	163,384
	NIH	Child Health and Human Development Extramural Research	CLEAR consortium: Discovering		Columbia University		P01HD093363	93.865	460,645	1,315,953	1,958,860
					University of Texas at Austin				1,312	-	-
					Children's Hospital Boston				180,950	-	-
	NIH	Child Health and Human Development Extramural Research	The Indiana University-Ohio St	Indiana University		9600-CCHMC	P30HD106451	93.865	-	10,834	10,834
	NIH	Child Health and Human Development Extramural Research	Xenobase: a Xenopus Model Organ		University of Calgary		P41HD064556	93.865	612,329	1,032,884	1,645,213
	NIH	Child Health and Human Development Extramural Research	Pediatric HIV/AIDS Cohort Stud	Harvard Medical School		117267-0184-5119274	PHD103133A	93.865	-	23,200	23,200
	NIH	Child Health and Human Development Extramural Research	SPR301160: PRECISE Trial Stanski [10058860-26-CINC] SPR301160 08/01/2023 (version 0)	University of Utah		10058860-26-CINC	PL1HD105462	93.865	-	1,818	1,818
	NIH	Child Health and Human Development Extramural Research	Establishment of the meiotic c				R00HD097285	93.865	-	326,418	326,418
	NIH	Child Health and Human Development Extramural Research	Genomic and functional analyse				R00HD104902	93.865	-	263,974	263,974
	NIH	Child Health and Human Development Extramural Research	Molecular signaling in uterine				R01HD068524	93.865	-	400,984	400,984
	NIH	Child Health and Human Development Extramural Research	A Cognitive Test Battery for I	University of California-Davis		1580GYB180	R01HD076189	93.865	-	194,816	194,816
	NIH	Child Health and Human Development Extramural Research	SPR400052: Improving ADHD Teen Driving - Renewal R01HD084430 09/16/2024 (version 0)				R01HD084430	93.865	-	394,595	394,595
	NIH	Child Health and Human Development Extramural Research	Cognitive Outcome Measures in		Colorado State University		R01HD093754	93.865	18,933	398,785	417,718
	NIH	Child Health and Human Development Extramural Research	Improving the Detection of ST	Children's National Medical Center			R01HD094213	93.865	-	71,267	71,267
	NIH	Child Health and Human Development Extramural Research	Exploring vascular-mesenchymal				R01HD094698	93.865	-	3,925	3,925
	NIH	Child Health and Human Development Extramural Research	Dosing and Pilot Efficacy of 2		Connecticut Childrens Medical Center		R01HD094862	93.865	119,179	477,623	638,956
					University of Cincinnati				42,154	-	-
	NIH	Child Health and Human Development Extramural Research	Dosing and Pilot Efficacy of 3		Children's Hospital Boston		GENFD0001702903	93.865	-	173,483	173,483
	NIH	Child Health and Human Development Extramural Research	Stress Hydrocortisone In Pedia				R01HD096901	93.865	-	37,945	37,945
	NIH	Child Health and Human Development Extramural Research	Deciphering the pathophysiology		Colorado State University		R01HD098280	93.865	-	13,363	13,363
	NIH	Child Health and Human Development Extramural Research	Executive Function Outcome Mea				R01HD099150	93.865	-	96,271	96,271
	NIH	Child Health and Human Development Extramural Research	Improving the Effectiveness an		University of Cincinnati		015953-0002	93.865	-	23,735	23,735
	NIH	Child Health and Human Development Extramural Research	Genomics of bone and body comp		Children's Hospital of Philadelphia		GRT-00006001	93.865	-	95,318	95,318
	NIH	Child Health and Human Development Extramural Research	Enhancing Nursing Care Reliabi		Ohio State University		60077379	93.865	-	178,934	178,934
	NIH	Child Health and Human Development Extramural Research	Skeletal Health and Bone Marro		Children's Hospital Boston		Boston_Sub_TBd	93.865	-	34,504	34,504
	NIH	Child Health and Human Development Extramural Research	SPR201495: PROMPT Bolus PA-18-091 SPR201495 09/11/2020 (version 0)		Children's Hospital of Philadelphia		PA-18-091	93.865	-	235,045	494,960
	NIH	Child Health and Human Development Extramural Research	Integrating genomic studies of		Univ of California			93.865	48,604	-	-
					University of Exeter				62,727	-	-
					University of Gothenburg				67,496	-	-
					Vanderbilt University				81,088	-	-
	NIH	Child Health and Human Development Extramural Research	A randomized controlled trial	University of California-Davis		A21-0255-S001	R01HD102571	93.865	-	53,950	53,950
	NIH	Child Health and Human Development Extramural Research	Endocannabinoid Signaling duri				R01HD103475	93.865	-	404,811	404,811
	NIH	Child Health and Human Development Extramural Research	Automated Risk Assessment for		University of Pittsburgh		R01HD103630	93.865	198,959	526,128	725,087
	NIH	Child Health and Human Development Extramural Research	Leveraging the electronic heal				R01HD103654	93.865	-	480,581	480,581
	NIH	Child Health and Human Development Extramural Research	Implementing a Social Determi		University of Massachusetts		SUB00000447	93.865	-	16,558	16,558
	NIH	Child Health and Human Development Extramural Research	SPR300575: Pena Sabia from University of Buffalo R1304645 SPR 03/18/2022 (version 0)		University of Buffalo		R1304645	93.865	-	32	32
	NIH	Child Health and Human Development Extramural Research	Obesity Prevention Targets for		Colorado State University		G-50243-01	93.865	-	219,027	219,027
	NIH	Child Health and Human Development Extramural Research	Behavior Measure for Children		University of Colorado		R01HD105679	93.865	54,844	382,479	437,323
	NIH	Child Health and Human Development Extramural Research	Prevention of behavior problem		The Ohio State University Research Fnd		R01HD105727	93.865	37,897	734,036	796,893
					Johns Hopkins University				24,960	-	-
					Northeastern University				99,365	401,030	685,517
	NIH	Child Health and Human Development Extramural Research	Evaluating additive effects of		Research Inst. at Nationwide Hos				185,122	-	-
	NIH	Child Health and Human Development Extramural Research	Using Dogs to Promote Therapeu				R01HD106416	93.865	-	288,591	288,591
	NIH	Child Health and Human Development Extramural Research	Precision Alentuzumab Therapy				R01HD107690	93.865	-	62,900	62,900
	NIH	Child Health and Human Development Extramural Research	FX ENTRAIN: Perturbation of ac		Brown University		R01HD108222	93.865	26,800	505,022	559,411
					University of Western Ontario				12,601	-	-
					University of Oklahoma				14,988	-	-

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure	
	NIH	Child Health and Human Development Extramural Research	Human Milk as a Biological Sys	University of Cincinnati		014666-0003	R01HD109915	93.865	\$ -	\$ 52,624	\$ 52,624	
	NIH	Child Health and Human Development Extramural Research	Screen to Prevent (S2P): Using		Children's Hospital of Philadelphia		R01HD110321	93.865	208,054	61,981	653,122	
					Children's National Medical Center				60,603	-	-	
					Medical College of Wisconsin				94,374	-	-	
					Nationwide Childrens Hospital				127,139	-	-	
					University of Utah				100,971	-	-	
	NIH	Child Health and Human Development Extramural Research	RCT of a Daily Living Skills I		University of North Carolina-Chapel Hill		R01HD113529	93.865	143,745	455,815	599,560	
	NIH	Child Health and Human Development Extramural Research	SPR301483: Tamm/Duncan R01 resub due 11.6.23 R01HD113534 SPR3 09/01/2024 (version 0)				R01HD113534	93.865	-	437,766	437,766	
	NIH	Child Health and Human Development Extramural Research	SPR400220: FRESH - Resubmission - 1 1R01HD114702-01A1 SPR4002 01/01/2025 (version 0)				R01HD114702	93.865	-	245,160	245,160	
	NIH	Child Health and Human Development Extramural Research	SPR400323: R01 UW-Madison-NICHD- Resubmission - 1 000004272 01/01/2025 (version 0)	University of Wisconsin-Madison		4272	R01HD114789	93.865	-	9,098	9,098	
	NIH	Child Health and Human Development Extramural Research	Determining the mechanism of m				R01HD116402	93.865	-	372,222	372,222	
	NIH	Child Health and Human Development Extramural Research	SPR400181: The role of HLA-C in chronic chorioamnionitis R01H 01/01/2025 (version 0)				R01HD116852	93.865	-	239,264	239,264	
	NIH	Child Health and Human Development Extramural Research	Capturing and characterizing t		Nationwide Childrens Hospital		R03HD111717	93.865	1,245	35,449	36,694	
	NIH	Child Health and Human Development Extramural Research	SPR400243: Barske R21 June 2024 R21HD118147 SPR400243 03/01/2025 (version 0)				R21HD118147	93.865	-	56,848	56,848	
	NIH	Child Health and Human Development Extramural Research	Pediatric Injury: Modules to Manage Medical Stress	University of Utah		1046978	R24HD096350	93.865	-	23,590	23,590	
	NIH	Child Health and Human Development Extramural Research	Evaluating Assessment and Medi		Children's Hospital Boston		R33HD100934	93.865	245,278	644,996	1,047,147	
					University of Pittsburgh				156,873	-	-	
	NIH	Child Health and Human Development Extramural Research	HEAL Initiative: Antenatal Opi	RTI International		5-312-0217179-035904	RL1HD104254	93.865	-	77,703	77,703	
	NIH	Child Health and Human Development Extramural Research	Enhancing Pediatric Treatment				T32HD068223	93.865	-	271,552	271,552	
	NIH	Child Health and Human Development Extramural Research	SPR202089: Viaks T32 Renewal 2020 T32HD069054 SPR202089 05/01/2021 (version 0)				T32HD069054	93.865	-	193,765	193,765	
	NIH	Child Health and Human Development Extramural Research	dGTEX BPC Participation	The Nat'l Disease Research Interchange		141143/1U24HD106537-01	U24HD106537	93.865	-	19,419	19,419	
	NIH	Child Health and Human Development Extramural Research	Translational medicine and mee		University of California, Riverside		U54HD104461	93.865	191,460	605,489	1,097,788	
					University of Oklahoma				6,754	-	-	
					University of Texas Southwestern				294,085	-	-	
	NIH	Child Health and Human Development Extramural Research	NICHD Neonatal Research Networ	RTI International		UG1HD027853	UG1HD027853	93.865	-	782,495	782,495	
	NIH	Child Health and Human Development Extramural Research	Outcomes of Babies with Opioid				UG1HD104254	93.865	-	163,479	163,479	
	NIH	Child Health and Human Development Extramural Research	HEAL initiative: Neonatal Opi				UG1HD107616	93.865	-	48,589	48,589	
	NIH	Child Health and Human Development Extramural Research	SPR300346: Marhar - HEAL initiative: Neonatal Opioid Withdraw 09/29/2021 (version 0)	RTI International		1U24HD107621	U24HD107621	93.865	-	28,499	28,499	
	NIH	Child Health and Human Development Extramural Research	SPR300886: Marhar - HEAL initiative: Neonatal Opioid Withdraw 09/01/2023 (version 0)				UG1HD107616	93.865	-	236,871	236,871	
	NIH	Child Health and Human Development Extramural Research	Adolescent Medicine Trials Net	Florida State University		R000003155	UM2HD111102	93.865	-	91,280	91,280	
		Child Health and Human Development Extramural Research Total							4,094,327	15,883,818	19,978,145	
	ACL	Developmental Disabilities Basic Support and Advocacy Families	Empowering Families	Ohio Coalition for the Education of Chil		Riddle_OCECD		93.630	-	15,741	15,741	
		Developmental Disabilities Basic Support and Advocacy Grants Total							-	15,741	15,741	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Elizabeth Coffey F32 Transfer				F32DK128979	93.847	-	109	109	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	The Role of DDX41 in Inherited				K01DK121733	93.847	-	11,834	11,834	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Role of VPS4A and ESCRT-III in				K01DK129270	93.847	-	170,109	170,109	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Microbial regulation of intest				K01DK135647	93.847	-	133,595	133,595	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Bridging the gap of late gesta				K08DK131259	93.847	-	190,232	190,232	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Commensal bacterial metabolism				K08DK134884	93.847	-	147,991	147,991	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Pittsburgh UTI Study-Katie For	University of Pittsburgh		AWD00005622(137493-1)	K23DK129783	93.847	-	1,500	1,500	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Disrupted sleep architecture i				K23DK135797	93.847	-	245,955	245,955	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Digestive Health Center (DHC)				P30DK078392	93.847	-	1,112,598	1,112,598	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Personalized Cystic Fibrosis T		Cedars-Sinai Medical Center		P30DK117467	93.847	122,955	986,632	1,109,587	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	SPR400185: Mohan PCEN Grant 3200950824 SPR400185 09/01/2023 (version 0)	Children's Hospital of Philadelphia		3200950824	P50DK114786	93.847	-	28,289	28,289	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Adolescent Bariatric Surgery:				R01DK080020	93.847	-	160,464	160,464	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	SPR400259: Tiao R01 Renewal Resubmission - Feb 2024 R01DK0915 03/05/2025 (version 0)				R01DK091566	93.847	-	99,402	99,402	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	SPR400269: Mielchke R01 Renewal (YRs 11-15) 2R01DK095001-10 SP 03/15/2025 (version 0)				R01DK095001	93.847	-	125,186	125,186	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Immunopathogenesis of non-alco				R01DK099222	93.847	-	156,119	156,119	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	On the regulation of hepatic g	University of Cincinnati		014965-00002	R01DK106364	93.847	-	22,348	22,348	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Epigenetic control of antimicrobial immunity in the intestine				R01DK114123	93.847	-	42,646	42,646	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Host integration of commensal				R01DK116868	93.847	-	521,106	521,106	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Molecular targets in cholestas				R01DK117266	93.847	-	125,117	125,117	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Biomarkers for Urinary Tract I	University of Pittsburgh		AWD00000120 (132569-2)	R01DK118033	93.847	-	55,598	55,598	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Surgical or Medical Treatment		University of Colorado		R01DK119450	93.847	42,576	406,247	448,823	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Molecular regulation of hepati				R01DK120765	93.847	-	169,931	169,931	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	SPR400030: Salomonis Northwestern sub 60067357-CCHMC SPR40003 06/03/2023 (version 0)	Northwestern University Medical School		60067357-CCHMC	R01DK120842	93.847	-	77,753	77,753	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Sex Proteins Modulate Genomic				R01DK123092	93.847	-	353,871	353,871	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	SPR300980: R01 Han Case Western SubK_Wells [RESS16540] SPR300 01/01/2023 (version 0)	Case Western University		RESS16540	R01DK123299	93.847	-	2,334	2,334	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Microbiota-mediated fibrotic r		University of North Carolina		5117429	R01DK124617	93.847	-	9,081	9,081
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Host and viral determinants of		Children's Hospital of Philadelphia		25460-GRT-00000414	93.847	-	342,477	342,477	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Determinants of inception of i		Massachusetts General Hospital		239459	R01DK127171	93.847	-	64,319	64,319
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Changing Health And Lifestyle		University of Delaware		R01DK128525	93.847	22,204	71,337	93,541	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Cyt induction and growth in A				R01DK129238	93.847	-	286,854	286,854	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	SPR400056: Park R01 from Northwestern - Bruggman 60067345 CCH 10/15/2023 (version 0)	Northwestern University Medical School		60067345 CCHMC	R01DK131052	93.847	-	63,607	63,607	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Contributions of the enterocy				R01DK132043	93.847	-	429,606	429,606	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Role of Etv4 and Etv5 in the s		Northwestern University		R01DK132052	93.847	1,544	406,442	407,986	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Multi-parametric quantitative				R01DK132346	93.847	-	542,049	542,049	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Precise Infliximab Exposure an		Children's Hospital Los Angeles		R01DK132408	93.847	5,499	803,786	941,304	
					Indiana University				41,192	-	-	
					Medical College of Wisconsin				15,005	-	-	
					Nationwide Childrens Hospital				25,993	-	-	
					Nemours Children's Clinic				6,451	-	-	
					Stanford University				17,768	-	-	
					University of California, San Diego				25,610	-	-	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Targeting POGGLUT1 to promote b				R01DK132751	93.847	-	161,309	161,309	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Diabetic Memory in Hematopoiet				R01DK133145	93.847	-	428,586	428,586	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Cutaneous biomarkers of pediat		University of California, San Diego		R01DK133198	93.847	293,170	407,083	700,253	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Artificial Intelligence to Pre	University of Alabama-Birmingham		000537127-SC002	R01DK133539	93.847	-	15,275	15,275	
	NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Oral Feeding Difficulty in Lar	The Nemours Foundation		R01DK134499	R01DK134499	93.847	-	22,140	22,140	

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		RNA silencing machinery in ext		Vanderbilt University		R01DK134646	93.847	\$ 44,017	\$ 866,690	\$ 910,707
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Organoid-guided Precision Hepa				R01DK135478	93.847	-	622,658	622,658
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Genetic and Small Molecule Reg		University of Pittsburgh		R01DK135479	93.847	15,260	550,828	566,088
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		A Novel Obesity Prevention Pro				R01DK135497	93.847	-	358,555	358,555
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR400166: CHICKADEE Johns Hopkins 2023 2006624323 SPR400166 03/15/2024 (version 0)	Johns Hopkins School of Medicine			2006624323 R01DK135518	93.847	-	43,396	43,396
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Liver-Gut-Microbiome Axis in P	Baylor College of Medicine			R01DK135602	93.847	-	29,650	29,650
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		The role of serpins and LRPI i				R01DK136512	93.847	-	382,255	382,255
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Mechanistic and Therapeutic Ro	University of California-Davis			A24-0282-S001 R01DK136815	93.847	-	376,226	376,226
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Epigenetic regulation of intes				R01DK137771	93.847	-	429,839	429,839
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR400382: Huppert - Cornell R01 Sub - Mechanisms of epitheli 07/15/2024 (version 0)	Weill Cornell Medical College			1074 R01DK138677	93.847	-	250,366	250,366
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Protein biomarkers to predict	University of Minnesota			N010838401 R01DK138809	93.847	-	7,714	7,714
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR301446: 10.5.23 Azouz R01 R01DK140127 SPR301446 08/15/2024 (version 0)				R01DK140127	93.847	-	422,791	422,791
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR400239: 01.18.24 Lim_Sub to JHU 2006579801 SPR400239 09/10/2024 (version 0)	Johns Hopkins University			2006579801 R01DK141455	93.847	-	72,440	72,440
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR400022: Lucas NIH Skeletal Feb 2024 R01DK141465 SPR400022 09/20/2024 (version 0)		University of Alabama at Birmingham		R01DK141465	93.847	17,674	294,678	312,352
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		ROLE OF CIRCADIAN RHYTHM AND I		Biomedical Research Foundation		R03DK130908	93.847	9,920	-	9,920
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR202609: Beta Cell Function [R03DK131156] SPR202609 02/01/2022 (version 0)				R03DK131156	93.847	-	42,310	42,310
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Advanced Mouse Models of DDX41				R03DK140185	93.847	-	83,777	83,777
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR301258: Abu-El-Hajja - R13 - PancreasFest 2024 [1R13DK1410 07/01/2024 (version 0)				R13DK141076	93.847	-	9,000	9,000
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Fibrosis Beyond the Core: A Ne				R21DK133562	93.847	-	160,378	160,378
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		PAINED: Project Addressing Ine	Children's National Medical Center			R61DK135406	93.847	-	17,383	17,383
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		A generalizable framework for		University of Pittsburgh		RC2DK122376	93.847	143,263	762,200	1,168,143
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR301159: Abu-El-Hajja - Sub Protein biomarkers N010838401 S 09/22/2023 (version 0)	University of Minnesota			N010838401 R01DK138809	93.847	-	22,312	22,312
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Pediatric Gastroenterology and				T32DK007727	93.847	-	561,811	561,811
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR300729: Zeller- Powers_T32 2022 Renewal T32DK063929 SPR3007 07/01/2023 (version 0)				T32DK063929	93.847	-	312,310	312,310
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Non Alcoholic Steatohepatitis		Cleveland Clin Lerner Col of Med of CWRU		1569 U01DK061732	93.847	-	32,605	32,605
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Clinical Center for Cholestati		Univ of Texas Southwestern		U01DK062497	93.847	137,767	400,480	538,247
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Limited Competition for Contin		Children's Mercy Kansas City		42189124 U01DK066143	93.847	-	86,926	86,926
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		CUREGN 2.0 - Midwest Pediatric		Nationwide Children's Hospital		700356-0625SA28 U01DK100866	93.847	-	12,938	12,938
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Defining the intestinal stem c				U01DK103117	93.847	-	197,600	197,600
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		INSPPIRE: A Longitudinal Cohor		University of Iowa		S02042-03 U01DK108334	93.847	-	221,738	221,738
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Pediatric Acute Liver Failure		Lurie Children's Hospital of Chicago		901628-CCH U01DK127995	93.847	-	11,721	11,721
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Clinical, imaging, and endosco		Connecticut Children's Medical Center		1620 U01DK134356	93.847	-	191,637	191,637
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Cincinnati Children's Clinical				U01DK134976	93.847	-	323,732	323,732
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		SPR400099: McCracken RBK 130112 SPR400099 08/01/2023 (version 0)		Brigham & Women's Hospital		130112 U24DK135157	93.847	-	90,157	90,157
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Cincinnati Cooperative Center				U54DK126108	93.847	-	829,975	829,975
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Pediatric Acute Liver Failure		Lurie Children's Hospital of Chicago		901628-CCH UDK127995A	93.847	-	7,957	7,957
NIH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Modeling diabetes using an int		University of Illinois at Chicago		UH3DK119982	93.847	39,733	63,028	107,210
					University of North Texas				4,449	-	-
	Diabetes, Digestive, and Kidney Diseases Extramural Research Total								1,294,730	18,550,978	19,845,708
NIH	Discovery and Applied Research for Technological Innovations to Improve Human Health		MRI and Deep Learning for Earl				R01EB029944	93.286	-	186,954	186,954
NIH	Discovery and Applied Research for Technological Innovations to Improve Human Health		Quantification of Liver Fibros		New York University School of Medicine		R01EB030582	93.286	19,751	501,712	542,666
					Univ of Michigan				3,149	-	-
					University of Wisconsin System				18,054	-	-
NIH	Discovery and Applied Research for Technological Innovations to Improve Human Health		MRI-Compatible Robot for Real-		Children's National Medical Center		30006761-01 R01EB031084	93.286	-	187,737	187,737
NIH	Discovery and Applied Research for Technological Innovations to Improve Human Health		Center for Innovative Diagnost		Johns Hopkins University		2006251659 U54EB007958	93.286	-	179,693	179,693
	Discovery and Applied Research for Technological Innovations to Improve Human Health Total								40,954	1,056,096	1,097,050
NIH	Drug Abuse and Addiction Research Programs		Role of Siglec-1 in HIV Intera		University of Cincinnati		R01DA051895	93.279	16,167	365,726	381,893
NIH	Drug Abuse and Addiction Research Programs		Modeling HIV and methamphetamine		University of Cincinnati		R01DA056903	93.279	20,749	536,937	557,686
NIH	Drug Abuse and Addiction Research Programs		Automated Substance Use Detect				R03DA054256	93.279	-	20,963	20,963
NIH	Drug Abuse and Addiction Research Programs		Omics analysis of HIV during s		University of Cincinnati		014150-00002 R33DA048439	93.279	-	37,239	37,239
NIH	Drug Abuse and Addiction Research Programs		SPRINT: Signature for Pain Rec		Stanford University		63308247-144386 R33NS114926	93.279	-	399,915	399,915
NIH	Drug Abuse and Addiction Research Programs		4/6 HBGD Prenatal Experiences		University of Cincinnati		U01DA055342	93.279	91,342	1,764,224	1,855,566
NIH	Drug Abuse and Addiction Research Programs		HEALthy Brain and Child Develo		University of California San Diego		KR 705046 U24DA055325	93.279	-	91,004	91,004
NIH	Drug Abuse and Addiction Research Programs		A cohort study of pain, psycho		Yale		CON-80004834 (GR122619) UG1DA015831	93.279	-	139,629	139,629
	Drug Abuse and Addiction Research Programs Total								128,258	3,355,637	3,483,895
HRSA	Emergency Medical Services for Children		Emergency Medicine Services fo		Medical College of Wisconsin		U0322684	93.127	32,361	352,571	545,452
					Washington University				160,520	-	-
	Emergency Medical Services for Children Total								192,881	352,571	545,452
NIH	Environmental Health		SPR400138: Yelton-Laue R00 Sub 018539-9351 SPR400138 09/01/2024 (version 0)		University of Massachusetts		018539-9351 R00ES034086	93.113	-	69,546	69,546
NIH	Environmental Health		Contribution of Thirdhand Smoke to Overall Tobacco Smoke				R01ES027815	93.113	-	199,192	199,192
NIH	Environmental Health		SPR300984: Buckley ONES UNC [5129474] SPR300984 08/01/2023 (version 0)		University of North Carolina		5129474 R01ES030078	93.113	-	25,613	25,613
NIH	Environmental Health		Effects of DDE exposure on adi		University of Southern California		129965417 R01ES030364	93.113	-	5,144	5,144
NIH	Environmental Health		SPR201104: ADVOCATE: Prevalence and Clinical Correlates of TH 08/15/2019 (version 0)		University of Cincinnati		R01ES030743	93.113	26,924	25,298	96,519
					San Diego St. Univ. Research Foundation				44,297	-	-
NIH	Environmental Health		Epigenetics, Air Pollution, an		University of Cincinnati		1R01ES031054-01A1 R01ES031054	93.113	-	154,771	154,771
NIH	Environmental Health		Longitudinal Impact of Air Pol				R01ES031621	93.113	30,637	847,959	912,633
					University of Cincinnati				34,037	-	-
NIH	Environmental Health		Gene-pesticide interactions an				R01ES032270	93.113	-	504,181	504,181
NIH	Environmental Health		Gestational PFAS Mixture Expos		Brown University		1R01ES032836-01 R01ES032836	93.113	-	65,995	65,995
NIH	Environmental Health		Impact of pre- and postnatal c		University of Pennsylvania		582722 R01ES033054	93.113	-	160,706	160,706
NIH	Environmental Health		OPEs and Adolescent Adiposity		University of Nevada, Las Vegas		GR16780 R01ES033200	93.113	-	151,501	151,501

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
	NIH	Environmental Health	Investigating the Impact of Ph	University of North Carolina			5129586 R01ES033252	93.113	\$ -	\$ 364,797	\$ 364,797
	NIH	Environmental Health	Childhood and In-Utero Exposur	University of Cincinnati		014646-00002	R01ES034049	93.113	-	90,317	90,317
	NIH	Environmental Health	Pre- and postnatal chemical mi	University of Louisville		ULRF_22-1005-02	R01ES035133	93.113	-	57,295	57,295
	NIH	Environmental Health	A Residential Dust Control Int	Brown University			2114 R21ES034187	93.113	-	23,351	23,351
	NIH	Environmental Health	Research Innovations using Sen		University of Cincinnati		R21ES034592	93.113	59,574	106,947	166,521
	NIH	Environmental Health	SPR202215: Yelton Mount Sinai R35 0001147 SPR202215 04/01/2021 (version 0)	Ichahn School of Medicine at Mount Sinai			1147 R31ES030435	93.113	-	11,710	11,710
	NIH	Environmental Health	SPR400191: CECIL: id0035_BrunnaR01_UCab_November2024-October 09/24/2024 (version 0)	University of Cincinnati		016360-00002	R56ES036268	93.113	-	55,688	55,688
	NIH	Environmental Health	SPR400308: Agarwal T32 1020957 SPR400308 12/15/2024 (version 0)	University of Cincinnati			1020957 T32ES007250	93.113	-	82,736	82,736
	NIH	Environmental Health	SPR400226: T32 UC Stipend 1020895 SPR400226 07/06/2024 (version 0)	University of Cincinnati			1020895 T32ES010957	93.113	-	146,739	146,739
		Environmental Health Total							195,469	3,149,486	3,344,955
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR301348: Quijas_F31 F31NSI35995 SPR301348 09/30/2024 (version 0)				F31NSI35995	93.853	-	35,475	35,475
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR301349: Drake_F31 F31NSI36029 SPR301349 09/30/2024 (version 0)				F31NSI36029	93.853	-	37,824	37,824
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Electrical Stimulation of Indu	Kennedy Krieger Research Institute		2K12NS098482-06	K12NS098482	93.853	-	199,001	199,001
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Towards biomarkers of resilien				K23NS117734	93.853	-	195,820	195,820
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Mitogenic Activities in Neuf of				R01NS028840	93.853	-	546,342	546,342
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Comparison of Hemorrhagic and	University of Cincinnati		012830-00013	R01NS030678	93.853	-	153,603	153,603
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Supraspinal Processing of Sens		Universitat De Barcelona		R01NS039426	93.853	9,356	574,231	583,587
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Identification and reversal of				R01NS065020	93.853	-	369,931	369,931
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	A New Model to Identify Preter				R01NS094200	93.853	-	1,125,424	1,125,424
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	MiR-155 and RUNX function in n				R01NS097233	93.853	-	489,024	489,024
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Binding of Epstein Barr Virus		Univ of Pennsylvania		R01NS099068	93.853	60,214	717,801	790,704
					University of Cincinnati				12,689	-	-
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Mechanisms of Biguanide Sensit	Emory University			R01NS099162	93.853	6,846	57,748	64,594
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Distinct Mechanisms of Cognitive Behavioral Therapy Effects in Youth with Migraine: Insights from Neuroimaging and Quantitative Sensory Testing (The How and Why Youth with Headaches Get Better Study)				R01NS101321	93.853	-	274,626	274,626
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR301467: Sun R01 SubIn Yale Renewal CON-80005125(GR124426) 03/01/2024 (version 0)	Yale University School of Medicine		CON-80005125(GR124426)	R01NS103931	93.853	-	221,672	221,672
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	A novel smart patch for the f	University of Cincinnati		012058-002	R01NS103992	93.853	-	2,381	2,381
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Sensitization of developing se				R01NS105715	93.853	-	467,359	467,359
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Mechanisms linking hemostatic				R01NS107258	93.853	-	43,198	43,198
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Functional analysis of the mic				R01NS107453	93.853	-	244,599	244,599
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Headache Assessment of Childre	Columbia University		PECARN Headache	R01NS110826	93.853	-	36,561	36,561
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR201678: Thomas UCSF Sub FEB2019 - Resubmission - 1 [119973] 03/15/2020 (version 0)	UCSF Human Research Program		11997ac	R01NS111166	93.853	-	2,660	2,660
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Mechanisms of muscle afferent				R01NS113965	93.853	-	429,183	429,183
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Bystander gene deletions in ca	Emory University		A1166165	R01NS114074	93.853	-	55,237	55,237
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Uncovering treatment targets f	University of Minnesota		P008296601	R01NS115438	93.853	-	360,385	360,385
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	CNS in congenital DM1: pathoge				R01NS115662	93.853	-	330,673	330,673
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Diagnostic validity and safety	Johns Hopkins University		R01NS115929-01	R01NS115929	93.853	-	126,119	126,119
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Polyomic Predictors of Symptom	Pennsylvania State University		CCHMCNS115942	R01NS115942	93.853	-	93,181	93,181
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Role of mTOR in Circadian and	University of Florida		SUB00003646	R01NS117457	93.853	-	58,182	58,182
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Circuit defects underlying in	Univ of California Los Angeles		1580 G YB180	R01NS117597	93.853	-	136,998	136,998
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Seizures and Children's Outcom	Univ of California San Francisco		13490ac	R01NS119896	93.853	-	1,123	1,123
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	ROSE-LAWN	University of Cincinnati		013382-002	R01NS120493	93.853	-	6,584	6,584
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Identification of novel pathwa				R01NS120892	93.853	-	472,298	472,298
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Anti-epileptogenic role of mTO				R01NS121042	93.853	-	467,878	467,878
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	NSR- GENE (Neonatal Seizure Reg	University of California, San Francisco		13439ac	R01NS124051	93.853	-	8,696	8,696
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Roles of Gsx factors in basal				R01NS124660	93.853	-	796,821	796,821
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Understanding the Impact of Yo				R01NS125316	93.853	-	449,212	449,212
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	CMRO2 and Uncoupling of Oxidat	University of Virginia		AWD-004172.GR101205	R01NS125677	93.853	-	34,440	34,440
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Midbrain pathways for visual h		Northwestern University		R01NS126108	93.853	41,422	395,137	436,559
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Disrupted Spatial and Temporal				R01NS126289	93.853	-	673,007	673,007
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Self-Management Intervention f	Makerere Institute of Social Research		11V2	R01NS129041	93.853	-	33,259	33,259
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Defining the remote effects of	University of Cincinnati		014891-00002	R01NS129922	93.853	-	28,107	28,107
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	The title is Role of meningeal	Yale University School of Medicine		CON-80004496	R01NS130057	93.853	-	54,211	54,211
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Advancing CNS drug delivery vi		Indiana University		R01NS132504	93.853	62,693	477,482	540,175
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	AT1C is a novel molecular targ	Emory University		A1123806	R01NS132884	93.853	-	36,008	44,249
					University of North Carolina-Chapel Hill				2,529	-	-
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400024: Ratner NIH R01 2022 - Resubmission - 1 R01NS133200 09/10/2024 (version 0)	Ann & Robert H Lurie Children's Hospital			R01NS133200	93.853	39,886	286,691	327,557
					Miami University..				980	-	-
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400093: UCR subcontract - Resubmission - 1 S1865 SPR400093 06/14/2024 (version 0)	University of California Riverside		S1865	R01NS134914	93.853	-	90,544	90,544
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Systemic Enzyme Delivery by a		University of Cincinnati		R01NS138309	93.853	149,280	394,591	543,871
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400389: Lu NIH R01 June 2024 R01NS142389 SPR400389 06/15/2025 (version 0)				R01NS142389	93.853	-	2,217	2,217
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Epigenetic mechanisms of disru				R03NS133727	93.853	-	67,000	67,000
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR202655: MPI Altered PI3K signaling - Resubmission - 1 [R21 02/15/2022 (version 0)				R21NS121644	93.853	-	65,862	65,862
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR202702: Waclaw R21 Resub July 2021 [R21NS123974] SPR202702 03/01/2022 (version 0)				R21NS123974	93.853	-	14,821	14,821
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Ablating choroid plexus epithe	University of Cincinnati		014796-00002	R21NS127177	93.853	-	41,433	41,433
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	A Mobile Health Application to	Eysaz, Inc		Eysaz - Aungaroon, Gwali	R43NS129363	93.853	-	17,607	17,607
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Developing novel biomarkers of	Ann & Robert H Lurie Children's Hospital		901654-CHMC	R61NS122094	93.853	-	213	213
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400019: R61-33 Gato dar 6.20.24 - Resubmission - 1 R61NS13 09/17/2024 (version 0)				R61NS138647	93.853	-	294,537	294,537
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400288: 10.20.2023_Woo_Sub to UC 016325-00002 SPR400288 08/21/2024 (version 0)	University of Cincinnati		016325-00002	RF1NS036695	93.853	-	7,279	7,279
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Assessing the contribution of				RNS121644A	93.853	-	14,497	14,497
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Cerebrovascular Fellowship Tra - Socharew left 7/30/2022 - Sec 400501	University of Cincinnati		013104-002	T32NS047996	93.853	-	7,393	7,393
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400251: Chidambaran Spine Cardiac_U01 AWD00009952(200653-2) 09/05/2024 (version 0)	University of Pittsburgh		AWD00009952(200653-2)	U01HD116257	93.853	-	14,349	14,349
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Perinatal Arterial Stroke: A M	University of Cincinnati		011961-136901	U01NS106655	93.853	-	10,253	10,253
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	Pediatric Dose Optimization fo	Stanford University		63439899-319717	U01NS114042	93.853	-	330,266	330,266
	NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders	SPR400101: NN111 ExTINGUISH CTA - Wilson 000917-00024 SPR4001 09/01/2024 (version 0)	University of Cincinnati		000917-00024	U01NS120901	93.853	-	21,602	21,602

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		SPR400063: LAMA2 Mutations - Tian U01 - Resubmission - 1 7003 09/18/2023 (version 0)	Nationwide Children's Hospital		700337-0825SA13	U01NS124961	93.853	\$ -	\$ 882	\$ 882
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		Cincinnati Neuroscience Clinic	University of Cincinnati		015327-0003	U24NS107200	93.853	-	98,696	98,696
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		Brain Vascular Malformation Co	Univ of California		11614ac	US4NS065705	93.853	-	30,933	30,933
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		SPR301243: TAND Clustering TSC-related Rhabdomyomas GENFD0002 01/01/2024 (version 0)	Boston Medical Center		GENFD0002493976	US4NS092090	93.853	-	55,664	55,664
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		FOcal Cerebral Arteriopathy St	University of Cincinnati		014851-136901	UG3NS119702	93.853	-	7,997	7,997
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		A Phase 3 clinical trial of an	Childrens Hospital of Orange County			UG3NS129558	93.853	64,015	627,292	1,313,025
				Medical University South Carolina					77,988	-	-
				University of Georgia					108,733	-	-
				University of Iowa					434,997	-	-
NIH	Extramural Research Programs in the Neurosciences and Neurological Disorders		SPR400356: Modi UG3 UH3 resubmission due 3.9.23 UH3NS129558 05/01/2025 (version 0)				UH3NS129558	93.853	-	99,579	99,579
	Extramural Research Programs in the Neurosciences and Neurological Disorders Total								1,077,340	13,921,699	14,999,039
FDA	Food and Drug Administration_Research		SPR400235: Loew - MPDC YR1 710092-0825-SA5 SPR400235 08/01/2024 (version 0)	Nationwide Children's Hospital		710092-0825-SA5	P50FD007961	93.103	-	27,715	27,715
FDA	Food and Drug Administration_Research		SPR400359: Cash - OxiWear - Jan 1st 2025 IS00001001 SPR400359 01/01/2025 (version 0)	OxiWear Inc		IS00001001	P50FD007965	93.103	-	4,849	4,849
FDA	Food and Drug Administration_Research		Quercetin Chemoprevention for	University of North Carolina-Chapel Hill			R01FD006353	93.103	1,712	39,325	41,037
FDA	Food and Drug Administration_Research		Abatacept for the treatment of	Duke University			R01FD007267	93.103	16,580	198,199	221,837
				Labey Clinic, Inc.					1,237	-	-
				Mayo Clinic Rochester					5,821	-	-
FDA	Food and Drug Administration_Research		Sirolimus TSC Epilepsy Prevent	Ann & Robert H Lurie Children's Hospital			R01FD007275	93.103	2,355	473,296	714,629
				Children's Hospital Boston					28,964	-	-
				Stanford University					86,298	-	-
				Univ. of California					63,036	-	-
				University of Alabama at Birmingham					45,678	-	-
				University of North Carolina-Chapel Hill					15,002	-	-
FDA	Food and Drug Administration_Research		CONNECT 1906	Nationwide Children's Hospital		720733-0822-00	R01FD007283	93.103	-	8,799	8,799
FDA	Food and Drug Administration_Research		Phase 2 trial of	Nationwide Children's Hospital		710078-0523-00	R01FD007532	93.103	-	72,252	72,252
FDA	Food and Drug Administration_Research		CONNECT 2007: Phase I/II Study						1,396	25,460	26,856
FDA	Food and Drug Administration_Research		SPR300206: Trapnell - Retrospective Autoimmune PAP Natural Hi 09/15/2022 (version 0)	University of South Florida			R01FD007604	93.103	-	25,374	25,374
FDA	Food and Drug Administration_Research		SPR400073: Sabulski FDA-MSK AA Trial 2024 C22750418 SPR400073 09/05/2024 (version 0)	Memorial Sloan Kettering Cancer Center		C22750418	R01FD008175	93.103	-	2,176	2,176
FDA	Food and Drug Administration_Research		SPR400225: PKDnet: ARPKD Learning Network GRT-00004420 SPR40 09/15/2024 (version 0)	Children's Hospital of Philadelphia		GRT-00004420	R01FD008225	93.103	-	-	-
	Food and Drug Administration_Research Total								268,079	877,445	1,145,524
NIH	International Research and Research Training		SPR300267: Rohit UNC D43 Wits South Africa [5123999] SPR30026 09/01/2021 (version 0)	University of North Carolina			5123999 D43TW009774	93.989	-	28,116	28,116
NIH	International Research and Research Training		Reducing the Impact of Rheumat	Makerere Institute of Social Research		MakCHS06042022	D43TW012255	93.989	-	56,154	56,154
	International Research and Research Training Total								-	84,270	84,270
NIH	Lung Diseases Research		SPR301482: Phelan F30 - Pathogenesis of frequent asthma exace 09/07/2024 (version 0)				F30HL172613	93.838	-	26,310	26,310
NIH	Lung Diseases Research		Mucosal Associated Invariant T				F31HL167596	93.838	-	40,262	40,262
NIH	Lung Diseases Research		Personalized Model Systems to				K08HL144825	93.838	-	28,046	28,046
NIH	Lung Diseases Research		TGF-Beta Regulates CFTR-Mediat				K08HL151762	93.838	-	40,794	40,794
NIH	Lung Diseases Research		Using technology-assisted step				K23HL139992	93.838	-	15,505	15,505
NIH	Lung Diseases Research		SPR201966: Kramer: K08 Resubmission KHL151762A SPR201966 02/01/2021 (version 0)				KHL151762A	93.838	-	182,054	182,054
NIH	Lung Diseases Research		The RECOVER Post-Acute Sequela	Children's Hospital of Philadelphia		EHR-02-21	OT2HL161847	93.838	-	151,271	151,271
NIH	Lung Diseases Research		Pathogenesis-Based Diagnostics				R01HL085453	93.838	-	71,051	71,051
NIH	Lung Diseases Research		Pediatric Respiratory Illness	Kaiser Foundation Research Institute		RNG211577-CCHMC	R01HL121067	93.838	-	57,408	57,408
NIH	Lung Diseases Research		Regional monitoring of CF lung				R01HL131012	93.838	-	871,933	871,933
NIH	Lung Diseases Research		WT1 Regulation of Pulmonary Fi	University of Cincinnati		014530-0002	R01HL134801	93.838	-	39,730	39,730
NIH	Lung Diseases Research		Development of neonatal innate				R01HL142708	93.838	-	1,623	1,623
NIH	Lung Diseases Research		Sleep-Disordered Breathing in	University of Michigan		SUBK00015153	R01HL147261	93.838	-	45,503	45,503
NIH	Lung Diseases Research		Bedside Exclusion of Pulmonary	Wayne State University		WSUJ22071	R01HL148247	93.838	-	73,019	73,019
NIH	Lung Diseases Research		Perinatal Dysbiosis, Lung Deve	National Jewish Health			R01HL149366	93.838	4,529	10,792	15,321
NIH	Lung Diseases Research		Obesity and Childhood Asthma:	Indiana University		9941	R01HL149693	93.838	-	21,444	21,444
NIH	Lung Diseases Research		Role of GM-CSF in Alveolar Mac	University of Washington			R01HL149743	93.838	23,155	399,153	422,308
NIH	Lung Diseases Research		Genetic and hypoxic control of	University of Pittsburgh		AWD00008090 (139597-2)	R01HL151228	93.838	-	22,120	22,120
NIH	Lung Diseases Research		Imaging and Molecular Phenotyp				R01HL151588	93.838	-	793,381	793,381
NIH	Lung Diseases Research		A ROLE FOR EYA3 IN VASCULAR RE	University of Cincinnati			R01HL152094	93.838	-	314,712	314,712
NIH	Lung Diseases Research		Uterine signaling networks in	University of Cincinnati			R01HL153045	93.838	77,795	92,215	170,010
NIH	Lung Diseases Research		Penetrating the "Black box":	University of Minnesota			R01HL153108	93.838	121,224	411,177	569,013
				The Ohio State University					36,612	-	-
NIH	Lung Diseases Research		Tissue niches for ILC3 develop				R01HL155611	93.838	-	347,998	347,998
NIH	Lung Diseases Research		Epigenetic Regulation of the M				R01HL156860	93.838	-	436,930	436,930
NIH	Lung Diseases Research		Sox9 Regulation of Fibroblast	University of Cincinnati		014532-00002	R01HL157176	93.838	-	99,847	99,847
NIH	Lung Diseases Research		TRANSPiRE: A Prospective Cohor				R01HL157392	93.838	37,637	579,887	1,463,926
				Baylor College of Medicine,					349,378	-	-
				Children's Hospital of Philadelphia					173,972	-	-
				Dana Farber Cancer Institute					32,171	-	-
				Fred Hutchinson Cancer Research Center					151,166	-	-
				Seattle Children's Hospital					7,752	-	-
				UCSF Medical Center					69,139	-	-
				University of California					3,505	-	-
				University of Colorado					59,319	-	-
NIH	Lung Diseases Research		NAD-dependent Signaling and Pu	Indiana University		9295_CH	R01HL158108	93.838	-	20,276	20,276
NIH	Lung Diseases Research		Risk stratification in pulmona				R01HL160941	93.838	251,059	203,386	454,445
NIH	Lung Diseases Research		DLL4 in the Developing Lung an	Children's Mercy Hospital			42094127 R01HL162937	93.838	-	28,767	28,767
NIH	Lung Diseases Research		Derivation and Validation of t	Lurie Children's Hospital of Chicago		A23-0051-S002-CHMC	R01HL162692	93.838	-	73,081	73,081

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
	NIH	Lung Diseases Research	Ptdm3/16 Regulate Chromatin Ac				R01HL164414	93.838	\$ -	\$ 736,252	\$ 736,252
	NIH	Lung Diseases Research	SPR400381: Perl -MEOX2: A Critical Regulat - Resubmission - 1 06/01/2025 (version 0)				R01HL164418	93.838	-	3,151	3,151
	NIH	Lung Diseases Research	Trajectories of Regional Cardi				R01HL164420	93.838	-	841,436	841,436
	NIH	Lung Diseases Research	Defining PRC2 complex epigenom				R01HL166245	93.838	-	509,782	509,782
	NIH	Lung Diseases Research	Elucidating the FOXF1 gene reg				R01HL166283	93.838	-	451,495	451,495
	NIH	Lung Diseases Research	Early detection of pulmonary c				R01HL166335	93.838	-	589,351	589,351
	NIH	Lung Diseases Research	Lung developmental defects cau	Univ of Arkansas for Medical Sciences			55852 R01HL166748	93.838	-	100,161	100,161
	NIH	Lung Diseases Research	Role of alveolar fibroblasts i				R01HL167030	93.838	-	746,506	746,506
	NIH	Lung Diseases Research	SPR400357: Szczeniak_JHM Sub_6.12.2023 2006774405 SPR400357 05/15/2024 (version 0)	Johns Hopkins School of Medicine			2006774405 R01HL169330	93.838	-	23,465	23,465
	NIH	Lung Diseases Research	Calculating the Components of				R01HL173164	93.838	-	624,342	624,342
	NIH	Lung Diseases Research	SPR400050: Woods UCLA Simas Disease NIH 2024 17120000173165 S 07/15/2024 (version 0)	Univ of California			1.712E+13 R01HL174913	93.838	-	59,762	59,762
	NIH	Lung Diseases Research	Human gene transfer and macrop		University of South Florida		R33HL156888	93.838	169,546	724,958	912,554
					University of Cincinnati				18,050	-	-
	NIH	Lung Diseases Research	Pragmatic Research on Diuretic		Case Western Reserve University		R34HL158586	93.838	81,390	64,005	235,628
					Emory University				36,347	-	-
					RTI International				53,886	-	-
	NIH	Lung Diseases Research	Transcriptional and epigenetic				R35HL171346	93.838	-	1,252,816	1,252,816
	NIH	Lung Diseases Research	SPR400276: Deshmukh - Establishing lifelong trajectories of p 03/15/2025 (version 0)				R35HL177131	93.838	-	192,584	192,584
	NIH	Lung Diseases Research	SPR400342: Ziady SBIR Genecys OGNIH_Ziady SPR400342 04/30/2025 (version 0)	Orange Grove Bio LLC		OGNIH_Ziady	R43HL174181	93.838	-	10,208	10,208
	NIH	Lung Diseases Research	Pulmonary Development and Dise				T32HL007752	93.838	-	233,324	233,324
	NIH	Lung Diseases Research	SMURRF T35 Fellowship			THL113229C	THL113229C	93.838	-	71,680	71,680
	NIH	Lung Diseases Research	ORBEX: Primary Prevention of Asthma and Wheezing in Children	University of Arizona			PO 438886	93.838	-	326,792	326,792
	NIH	Lung Diseases Research	LungMap Phase II - Building a		Cedars-Sinai Medical Center		U01HL148856	93.838	12,871	35,126	80,084
					Massachusetts General Hospital				32,087	-	-
	NIH	Lung Diseases Research	Eliminating Monitor Overuse (E		Children's Hospital of Philadelphia		GRT-00001474	93.838	-	57,183	57,183
	NIH	Lung Diseases Research	SPR301478: Xu - A mechanistic 3D AI-powered map of genetic ch 09/01/2024 (version 0)				U01HL175383	93.838	-	582,613	582,613
	NIH	Lung Diseases Research	The LungMAP Data Coordination		RTI International		U24HL148865	93.838	120,544	842,544	1,365,867
					The Broad Institute Inc.				215,641	-	-
					Univ of California Santa Cruz				137,138	-	-
					Univ of Pennsylvania				50,000	-	-
	NIH	Lung Diseases Research	AZanthromycin Therapy in Prese	University of Arizona			653083 UH3HL147016	93.838	-	154,994	154,994
		Lung Diseases Research Total							2,325,913	14,734,205	17,060,118
	HRSA	Maternal and Child Health Federal Consolidated Programs	MCH Research Network Programs	Univ of Colorado Health Science Ct			FY24.609.020	93.110	-	9,771	9,771
		Maternal and Child Health Federal Consolidated Programs Total							-	9,771	9,771
	NIH	Medical Library Assistance	A Framework for Automated and				R01LM013222	93.879	-	111,989	111,989
	NIH		Situation Awareness to Improve	Children's Hospital of Philadelphia			R01LM013526	93.879	-	56,907	56,907
		Medical Library Assistance Total							-	168,896	168,896
	NIH	Mental Health Research Grants	Predicting Psychiatric Readmis				F31MH132265	93.242	-	2,719	2,719
	NIH	Mental Health Research Grants	A Family Navigator Interventio				K23MH125138	93.242	-	221,293	221,293
	NIH	Mental Health Research Grants	1/2 Anomalous Motor System Ply				R01MH095014	93.242	-	471,935	471,935
	NIH	Mental Health Research Grants	1/3 Effectiveness Trial of the	Florida State University		R000002935	R01MH121627	93.242	-	103,046	103,046
	NIH	Mental Health Research Grants	Longitudinal Examination of SI				R01MH122415	93.242	-	757,737	757,737
	NIH	Mental Health Research Grants	Molecular Dissection of Synapt	The University of Massachusetts, Amherst		21-015624 A00	R01MH122519	93.242	-	23,605	23,605
	NIH	Mental Health Research Grants	Parsing Neurobiological Bases		Purdue University		R01MH123831	93.242	22,345	228,627	334,871
					University of Cincinnati				83,899	-	-
	NIH	Mental Health Research Grants	Adaptive intervention to preve	University of Michigan			SUBK00021082	93.242	-	254,213	254,213
	NIH	Mental Health Research Grants	SPR400265: Airway inflammation and fear - Resubmission - 1 01 09/01/2024 (version 0)	University of Cincinnati			016028-00002	93.242	-	58,820	58,820
	NIH	Mental Health Research Grants	Developing 3D brain circuits o		University of Cincinnati			93.242	45,344	69,849	115,193
	NIH	Mental Health Research Grants	SPR400010: Burkett - R34 - NIH - 10/16/23 R34MH137224 SPR4000 08/12/2024 (version 0)				R34MH137224	93.242	-	166,003	166,003
	NIH	Mental Health Research Grants	Airway inflammation and fear:	University of Cincinnati			R56MH127043	93.242	-	18,839	18,839
	NIH	Mental Health Research Grants	ADHD PreSMART: ADHD PreSMA Res				R61MH135994	93.242	-	350,762	350,762
		Mental Health Research Grants Total							151,588	2,727,448	2,879,036
	NIH	National Center on Sleep Disorders Research	Improving Outcomes in Pediatr				R00HL144822	93.233	-	65,549	65,549
	NIH	National Center on Sleep Disorders Research	SPR400290: Hogenssch R01 Sub WU Mar 2024 WU-25-0429 SPR400290 12/16/2024 (version 0)	Washington University		WU-25-0429	R01HL173976	93.233	-	3,775	3,775
	NIH	National Center on Sleep Disorders Research	Positive Airway Pressure for t	University of Miami		0500001439	R33HL151253	93.233	-	329,948	329,948
	NIH	National Center on Sleep Disorders Research	SPR301447: DoSA Amin R33 R33HL165366 SPR301447 09/01/2024 (version 0)		Brigham and Women's Hospital		R33HL165366	93.233	483,202	730,219	2,113,764
					Children's Hospital Los Angeles				51,908	-	-
					Children's Hospital of Philadelphia				188,929	-	-
					Harvard Pilgrim Health Care, Inc.				29,852	-	-
					Old Dominion University Research Foundation				122,443	-	-
					Oregon Health & Science University				29,592	-	-
					Seattle Children's Hospital				187,443	-	-
					Univ of Michigan				189,519	-	-
					University of Southern California				100,657	-	-
	NIH	National Center on Sleep Disorders Research	Treatment of Obstructive Sleep	Oregon Health Sciences University		1021452_Cincinnati	R61HL165345	93.233	-	57,543	57,543
	NIH	National Center on Sleep Disorders Research	Randomized Control Trial of ox		Brigham and Women's Hospital		R61HL165366	93.233	115,487	119,924	1,012,917
					Case Western Reserve University				95,213	-	-
					Children's Hospital Boston				110,760	-	-
					Children's Hospital Los Angeles				199,097	-	-
					Children's Hospital of Philadelphia				76,399	-	-

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
					Eastern Virginia Medical School				\$ 17,427	\$ -	\$ -
					Harvard Pilgrim Health Care, Inc.				105,569	-	-
					Oregon Health & Science University				22,779	-	-
					Seattle Children's Hospital				31,783	-	-
					Univ of Michigan				57,257	-	-
					University of Southern California				61,222	-	-
			National Center on Sleep Disorders Research Total						2,276,538	1,306,958	3,583,496
HRSA	National Research Service Award in Primary Care Medicine		General Pediatrics Research Fe					93.186	-	526,097	526,097
			National Research Service Award in Primary Care Medicine Total						-	526,097	526,097
NIH	Nursing Research		Fostering medication adherence		Medical University South Carolina			93.361	33,298	12,985	48,136
					Research Inst. at Nationwide Hos				196	-	-
					North Carolina State University				1,657	-	-
NIH	Nursing Research		Randomized Controlled Trial of		University of Virginia			93.361	45,957	550,203	596,160
NIH	Nursing Research		Integrating clinician, caregiv	Akron Children's Hospital		23-0001-A0001-SUB02		93.361	-	83,828	83,828
NIH	Nursing Research		A socio-ecological approach fo		Nemours Children's Clinic, Jacksonville			93.361	24,378	602,645	695,603
					Children's Hospital of Philadelphia				51,848	-	-
					Emory University				16,732	-	-
NIH	Nursing Research		IMAAP: Development and evaluat					93.361	-	215,006	215,006
			Nursing Research Total						174,066	1,464,667	1,638,733
NIH	Oral Diseases and Disorders Research		Developmental roles of Nr2f1 a					93.121	-	41,865	41,865
NIH	Oral Diseases and Disorders Research		The role of Sonic hedgehog sig					93.121	-	39,861	39,861
NIH	Oral Diseases and Disorders Research		Stottmann R01 Subaward from Na	Nationwide Children's Hospital		700262-0622		93.121	-	8,802	8,802
NIH	Oral Diseases and Disorders Research		Regulation of Craniofacial Dev					93.121	-	428,227	428,227
NIH	Oral Diseases and Disorders Research		Development and evaluation of	Indiana University		9352-CHMC		93.121	-	35,592	35,592
NIH	Oral Diseases and Disorders Research		Predicting Gli3 regulatory act	The Jackson Laboratory		210391-0323-02		93.121	-	241,359	241,359
NIH	Oral Diseases and Disorders Research		SPR400016: Juang NIH R01DE032558 Resubmission 3/5/24 R01DE032 09/10/2024 (version 0)					93.121	-	477,324	477,324
NIH	Oral Diseases and Disorders Research		Molecular Regulation of Palate					93.121	-	461,689	461,689
NIH	Oral Diseases and Disorders Research		Molecular Basis of SIX2-relate					93.121	-	101,344	101,344
NIH	Oral Diseases and Disorders Research		Harnessing the therapeutic potential of neural crest cel	Phoenix Children's Hospital	Nationwide Childrens Hospital			93.121	12,007	1,637,469	1,649,476
NIH	Oral Diseases and Disorders Research		Velopharyngeal insufficiency f			SITZMAN-20-03		93.121	-	52,890	52,890
NIH	Oral Diseases and Disorders Research		Reduction of bloodstream infec		Brigham and Women's Hospital			93.121	14,821	331,139	661,696
					Dana Farber Cancer Institute				226,278	-	-
					University of Colorado				89,458	-	-
			Oral Diseases and Disorders Research Total						342,564	3,857,561	4,200,125
AHRQ	Research on Healthcare Costs, Quality and Outcomes		The Patient and Parent Perspec					93.226	-	34,416	34,416
AHRQ	Research on Healthcare Costs, Quality and Outcomes		AHRQ Mentored Clinical Scienc					93.226	-	110,158	110,158
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Diagnosis and management of pe	Stanford University		63291150-306760		93.226	-	36,753	36,753
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Achieving Pediatric Health Equ					93.226	-	385,453	385,453
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Examining the impact of health					93.226	-	452,026	452,026
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Developing and Validating an A		Children's Hospital of Philadelphia			93.226	4,097	410,802	424,110
					Massachusetts General Hospital,				9,211	-	-
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Comparing Family Decision Maki		University of Pittsburgh			93.226	8,821	393,241	402,062
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Standardization of Evaluation	University of Michigan		SUBK00017768		93.226	-	29,568	29,568
AHRQ	Research on Healthcare Costs, Quality and Outcomes		SPR400267: Beal R03 Sub to Rutgers - Med Homes 3526 SPR400267 09/30/2024 (version 0)	Rutgers				93.226	-	7,731	7,731
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Spread of Safety Interventions	Children's Hospital Boston		RHS027401A		93.226	-	7,767	7,767
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Re-engineering Patient and Fam	Children's Hospital Boston		GENFD0002282084		93.226	-	191,882	191,882
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Digital Innovation, Simulation		Ann & Robert H Lurie Children's Hospital			93.226	62,189	454,151	545,046
					Children's Hospital Boston			93.226	28,706	-	-
					Children's Hospital Med Center of Akron			93.226	19,963	217,107	387,354
					Medical University South Carolina				30,966	-	-
					Seattle Children's Hospital				27,776	-	-
					Univ of Pennsylvania				38,007	-	-
					University of Chicago Research Admin				21,366	-	-
					Virginia Commonwealth University				32,169	-	-
AHRQ	Research on Healthcare Costs, Quality and Outcomes		Inform shared decision-making	Seattle Children's				93.226	-	83,259	83,259
			Research on Healthcare Costs, Quality and Outcomes Total						283,271	2,814,314	3,097,585
NIH	Research Related to Deafness and Communication Disorders		SPR400170: Blankenship - K23 - 02-2024 K23DC022304 SPR400170 12/01/2024 (version 0)					93.173	-	84,258	84,258
NIH	Research Related to Deafness and Communication Disorders		Prevention of Otitis with		Oregon Health & Science University			93.173	254,927	198,264	465,430
					Portland VA Research Foundation				12,239	-	-
NIH	Research Related to Deafness and Communication Disorders		SPR301280: de Alarcon-Eddins Central Florida R01 GR108175 SPR 07/17/2023 (version 0)	University of Central Florida		GR108175		93.173	-	33,958	33,958
NIH	Research Related to Deafness and Communication Disorders		Technology-assisted language i		University of Colorado			93.173	162,354	340,950	503,304
NIH	Research Related to Deafness and Communication Disorders		Earliest predictors of languag		University of Cincinnati,			93.173	55,666	650,764	706,430
NIH	Research Related to Deafness and Communication Disorders		Neuroimaging Reveals Treatment	University of Toronto		2-515357		93.173	-	73,973	73,973
NIH	Research Related to Deafness and Communication Disorders		SPR400275: Resub:Temple University/Heller Murray (de Alarcon) 08/13/2024 (version 0)	Temple University College of Public Heal		272837-CHMC		93.173	-	154,078	154,078
NIH	Research Related to Deafness and Communication Disorders		Society of Ears, Nose, and Thr	Mayo Clinic Arizona		CIN-312896		93.173	-	6,676	6,676
NIH	Research Related to Deafness and Communication Disorders		Mobile technologies for delive		University of Pretoria			93.173	10,759	17,637	28,396
NIH	Research Related to Deafness and Communication Disorders		Investigating the contribution	University of Cincinnati		015911-00003		93.173	-	58,882	58,882
NIH	Research Related to Deafness and Communication Disorders		Uncovering the Neural Mechanis					93.173	-	158,571	158,571
NIH	Research Related to Deafness and Communication Disorders		SPR400040: Moore Mobile Tech R33 Transition Package R33DC0195 07/01/2024 (version 0)		University of Pretoria			93.173	50,743	15,011	65,754
NIH	Research Related to Deafness and Communication Disorders		Effects of Hypoglossal Nerve S	Massachusetts Ear & Eye Infirmary		MassEyeEar_Heubi		93.173	-	3,052	3,052
			Research Related to Deafness and Communication Disorders Total						546,688	1,796,074	2,342,762

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
SAMHSA	Substance Abuse and Mental Health Services_Projects of Regional and National Significance		Pediatric Integrated Post-Trauma	University of Utah		10060285-03-CCHMC	H79SM085051	93.243	\$ -	\$ 11,953	\$ 11,953
SAMHSA	Substance Abuse and Mental Health Services_Projects of Regional and National Significance		Implementation of Screening, B		University of Cincinnati		H79TI084035	93.243	27,724	887,697	915,421
	Substance Abuse and Mental Health Services_Projects of Regional and National Significance Total								27,724	899,650	927,374
CDC	Training and Clinical Skills Improvement Projects		Advancing the Epidemiology and	Indiana University		9782-CHMC	NU58IP000004	93.185	-	38,286	38,286
CDC	Training and Clinical Skills Improvement Projects		US Enhanced Surveillance Netwo				U01IP001155	93.185	-	2,533,848	2,533,848
	Training and Clinical Skills Improvement Projects Total								-	2,572,134	2,572,134
NIH	Trans-NIH Research Support		Engineering multi-organs in a				DP2DK128799	93.310	-	694,880	694,880
NIH	Trans-NIH Research Support		Cloud implementation of Xenbas				P41HD064556	93.310	-	201,108	201,108
NIH	Trans-NIH Research Support		COVID-19 Network of Networks -	Rutgers		SUB000002754	R33HD105619	93.310	-	25,505	25,505
NIH	Trans-NIH Research Support		Childhood Allergy and the NeOn	University of Wisconsin-Madison			3685 UG3OD035509	93.310	-	20,773	20,773
NIH	Trans-NIH Research Support		Developmental Impact of NICU E	Northwell Health			AWD00001795_Cincinnati_CR	93.310	-	51,645	51,645
	Trans-NIH Research Support Total								-	993,911	993,911
NIH	Vision Research		Predicting uveitis onset in ch		Children's Hospital Boston		R01EY030521	93.867	6,996	468,408	642,784
NIH	Vision Research				Emory University		R01EY030521	93.867	900	-	-
NIH	Vision Research		SPR201119: R01_Angelo-Ham_Oct 2018 1R01EY030521 SPR201119 09/30/2019 (version 0)		Wake Forest Univ School of Medicine		R01EY030521	93.867	166,480	-	-
NIH	Vision Research		Light regulated vascular devel				R01EY032029	93.867	-	141,021	141,021
NIH	Vision Research		dopamine LKB1 project	Baylor College of Medicine		Baylor_Lang	R01EY032566	93.867	-	321	321
NIH	Vision Research		Mechanisms of intrinsic light		University of Alabama at Birmingham		R01EY032752	93.867	135,802	-	135,802
NIH	Vision Research		Genomic analysis of microphtha				R01EY032976	93.867	-	233,015	233,015
NIH	Vision Research		Melanopsin-dependent light-evo				R01EY034456	93.867	-	326,654	326,654
NIH	Vision Research		Optimizing methotrexate use fo		Children's Hospital Boston		R01EY034565	93.867	24,529	386,792	667,515
					Children's Mercy Hospital				9,046	-	-
					Cleveland Clinic Foundation				236,408	-	-
					University of Nebraska Medical Center				10,740	-	-
NIH	Vision Research		Microphthalmia, anophthalmia a				R01EY035500	93.867	-	322,220	322,220
NIH	Vision Research		SPR400231: Owen R01 Transfer: ROP 1R56EY036091-01 SPR400231 09/30/2024 (version 0)		University of Utah		R56EY036091	93.867	35,792	246,521	282,313
NIH	Vision Research		Cataract Surgery Outcome Registry	Jach Center for Health Res Fds., Inc.		U10EY011751	U10EY011751	93.867	-	56,518	56,518
NIH	Vision Research		Adalimumab in Juvenile Idiopat	The Univ of California, San Francisco		11309ac_FEX	UG1EY029658	93.867	-	5,501	5,501
	Vision Research Total								626,693	2,186,971	2,813,664
NIH	Human Genome Research		Engaging adolescents in decis		Mayo Clinic Rochester		R01HG010166	93.172	49,737	129,999	179,736
NIH	Human Genome Research		Virus-driven human gene misreg				R01HG010730	93.172	-	189,047	189,047
NIH	Human Genome Research		Epigenome-wide variations and		University of Cincinnati		R01HG011411	93.172	5,895	820,920	826,815
NIH	Human Genome Research		Post-Transcriptional Regulator	Memorial Sloan Kettering Cancer Center		PO #C2420604	R01HG013328	93.172	-	96,124	96,124
NIH	Human Genome Research		Single-cell and single-molecul	The University of Chicago		AWD103412 (SUB00000762)	R21HG012423	93.172	-	18,201	18,201
NIH	Human Genome Research		SciDAP: next generation platfo	Datarium LLC			R42HG011219	93.172	-	82,453	82,453
NIH	Human Genome Research		Polygenic Risk Scores for Heal		Children's Hospital Boston		U01HG011172	93.172	19,331	563,821	715,455
					University of Cincinnati				132,303	-	-
NIH	Human Genome Research		SPR400129: CHOP Sub-In Supplement 2024 20642106/GRT-00000400-08/19/2024 (version 0)		Children's Hospital of Philadelphia		20642106/GRT-00000400-0425-82	93.172	-	30,950	30,950
NIH	Human Genome Research		CisBP and CisBP-RNA: web resou		University Health Network		U24HG013078	93.172	535,874	193,171	729,045
	Human Genome Research Total								743,140	2,124,686	2,867,826
NIH	Alcohol Research Programs		Therapeutic and mechanistic si		University of Cincinnati		014707-00002	93.273	-	27,585	27,585
	Alcohol Research Programs Total								-	27,585	27,585
CDC	Injury Prevention and Control Research and State and Community Based Programs		Evaluation of Return to School		University of Oregon		282080C	93.136	-	9,579	9,579
CDC	Injury Prevention and Control Research and State and Community Based Programs		Development of a Mental health				U01CE003163	93.136	-	496,761	496,761
	Injury Prevention and Control Research and State and Community Based Programs Total								-	506,340	506,340
NIH	National Center for Advancing Translational Sciences		Instrumenting the Delivery Sys		University of Cincinnati		012846-000011	93.350	-	333,891	333,891
NIH	National Center for Advancing Translational Sciences		Center for Clinical and Transl				R03TR004601	93.350	-	109,289	109,289
NIH	National Center for Advancing Translational Sciences		Urinary Lipidomic profile in F		University of Cincinnati		015695-00002	93.350	-	23,219	23,219
NIH	National Center for Advancing Translational Sciences		Clinical Trial Readiness - Pri		Children's Hospital Boston		GENFD0001706578	93.350	-	217,750	217,750
NIH	National Center for Advancing Translational Sciences		Modeling Progressive Familial		Vanderbilt University Medical Center		VUMC116723	93.350	-	163,027	163,027
NIH	National Center for Advancing Translational Sciences		Primary Immune Deficiency Trea		University of Colorado		U2CTR002818	93.350	23,570	5,530,277	5,553,847
NIH	National Center for Advancing Translational Sciences		Implementation of a Novel Viri		Wake Forest University Health Sciences		2322-45819-11000002557	93.350	-	71,357	71,357
NIH	National Center for Advancing Translational Sciences		SPR400327: DMAC- Baylor PIDTC UH3TR003908 SPR400327 08/15/2024 (version 0)		Baylor College of Medicine		UH3TR003908	93.350	-	12,000	12,000
NIH	National Center for Advancing Translational Sciences		Structure-function analysis of		University of Cincinnati		2UL1TR001425-05A1	93.350	-	1,960,378	1,960,378
	National Center for Advancing Translational Sciences Total								23,570	8,421,188	8,444,758
CDC	Occupational Safety and Health Program		Enhanced injury surveillance u				R01OH011996	93.262	-	626,400	626,400
CDC	Occupational Safety and Health Program		Defining the Role and Occupati				R21OH012679	93.262	-	211,001	211,001
CDC	Occupational Safety and Health Program		Newman UC sub T42 ERC Renewal		University of Cincinnati		1253 T42OH008432-16-00	93.262	-	18,524	18,524
	Occupational Safety and Health Program Total								-	855,925	855,925
CDC	Health Program for Toxic Substances and Disease Registry		SPR400321: PEHSU 2024-2027 UI 20420 SPR400321 09/01/2024 (version 0)		Univ of Illinois @ Chicago		UI 20420	93.161	-	23,703	23,703
	Health Program for Toxic Substances and Disease Registry Total								-	23,703	23,703
NIH	Cancer Control		SPR202692: Norris PHI-COG NCCORP PCR Work Order 2021 [UG1CA189 08/01/2021 (version 0)		Public Health Institute		UG1CA189955-08	93.399	-	1,274	1,274
	Cancer Control Total								-	1,274	1,274

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
	NIH	Research and Training in Complementary and Integrative Health	Dissecting Neural Mechanisms S				R01AT010171	93.213	\$ -	\$ 572,853	\$ 572,853
	NIH	Research and Training in Complementary and Integrative Health	Online Techniques and Educatio	Wake Forest University		1679-45117-11000000967	R01AT011502	93.213	-	39,032	39,032
	NIH	Research and Training in Complementary and Integrative Health	RELAXaHEAD: A Behavioral Appro	NYU Langone Health			119664 R01AT011875	93.213	-	9,004	9,004
	NIH	Research and Training in Complementary and Integrative Health	SPR400141: Crosby sub to Emory - R33 A1068286 SPR400141 09/01/2024 (version 0)	Emory University		A1068286	R33AT012421	93.213	-	76,506	76,506
	NIH	Research and Training in Complementary and Integrative Health	Integrative Training Program f	Emory University		A730969	R61AT012421	93.213	-	57,419	57,419
	NIH	Research and Training in Complementary and Integrative Health	Mind Body Balance for Pediatr		University of Colorado		U01AT010132	93.213	146,769	559,526	713,795
					University of Virginia				7,500	-	7,500
	NIH	Research and Training in Complementary and Integrative Health	Food-Body-Mind Intervention: P	Michigan State University			RC115611CCHMC	93.213	-	5,300	5,300
		Research and Training in Complementary and Alternative Medicine Total							154,269	1,319,640	1,473,909
	ACL	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	SPR202385: Wade_NIDILRR 12.21.2020 90IFRE0055-01-00 SPR202385 09/01/2021 (version 0)		Nationwide Childrens Hospital		90IFRE0055-01-00	93.433	19,480	24,400	71,308
					Xavier University				27,428	-	27,428
	ACL	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	SPR300259: Ayers subN Brandeis University PARENTING research 09/14/2021 (version 0)	Brandeis University			404244 90DPCP0012	93.433	-	15,015	15,015
	ACL	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	SPR200804: Oregon NIDILRR Resubmission [239530A] SPR200804 09/30/2018 (version 0)	University of Oregon		239530A	90DPHF003-01-00	93.433	-	5,877	5,877
	ACL	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	SPR300156: Ayers FIRP Research 2022-2025 90IFRE0062 SPR300156 09/01/2022 (version 0)				90IFRE0062	93.433	-	98,870	98,870
	ACL	ACL National Institute on Disability, Independent Living, and Rehabilitation Research	SPR300946: Wade 12/16/22 NIDILRR Submission 90IFRE0075 SPR300 09/01/2023 (version 0)				90IFRE0075	93.433	-	215,195	215,195
		ACL National Institute on Disability, Independent Living, and Rehabilitation Research Total							46,908	359,357	406,265
	NIH	Research Infrastructure Programs	SPR301473: Xenbase-NXR (Zorn/Horb) 54689 SPR301473 05/01/2024 (version 0)	Marine Biological Laboratory			54689 P400D010997	93.351	-	68,464	68,464
	NIH	Research Infrastructure Programs	A new mouse model to study GBA		Yale University		R21OD033660	93.351	60,732	118,159	178,891
	NIH	Research Infrastructure Programs	A validated mouse model of bro				R21OD034470	93.351	-	133,437	133,437
		Research Infrastructure Programs Total							60,732	320,060	380,792
	CDC	Rare Disorders: Research, Surveillance, Health Promotion, and Education	Woodward CDC NSBPR Registry 20				U01DD001279	93.315	-	56,689	56,689
		Rare Disorders: Research, Surveillance, Health Promotion, and Education Total							-	56,689	56,689
	NIH	Minority Health and Health Disparities Research	11/15/18. Bowers. Resub R01. L				R01MD013006	93.307	-	219,552	219,552
	NIH	Minority Health and Health Disparities Research	SPR301480: Mersha/Vaughn R21- DNA & Stress in Immigrants - Re 07/01/2024 (version 0)				R21MD019192	93.307	-	111,694	111,694
	NIH	Minority Health and Health Disparities Research	Growing and Sustaining Communi		University of Cincinnati		015322-0003	93.307	-	15,555	15,555
	NIH	Minority Health and Health Disparities Research	SPR400264: R41_STTR_Precision Quantumics Precision - Prasad, 01/01/2025 (version 0)		Precision Quantumics		R41MD019585	93.307	-	82,876	82,876
		Minority Health and Health Disparities Research Total							-	429,677	429,677
	AHRQ	National Research Service Awards_Health Services Research Training	Describing ventilator weaning		Children's Hospital of Philadelphia		3201350923 K12HS026393	93.225	-	134,819	134,819
		National Research Service Awards_Health Services Research Training Total							-	134,819	134,819
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	Setting Families on a Positive		Nationwide Childrens Hospital		90IFRE0055	93.433	22,710	15,549	38,259
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	Parents Empowering Parents: Na	Brandeis University			404244 90DPCP0012	93.433	-	4,551	4,551
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	Accessible Pregnancy Action Pl	Brandeis University			404234 90DPHF0011	93.433	-	2,710	2,710
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	Enhancing Parenting Skills: Application of a web-based three-tiered model	University of Oregon		239530A	90DPHF003-01-00	93.433	-	5,598	5,598
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	Impacts of Internalized, Inter				90IFRE0062	93.433	-	29,936	29,936
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	A Randomized Trial of I-INTEA				90IFRE0075	93.433	-	76,601	76,601
	ACL	Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	The Task Force for Global Heal	The Task Force for Global Health, Inc			NU380T000316	93.421	-	49,747	49,747
		Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health Total							22,710	184,692	207,402
	NIH	Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	Accelerating Delivery of rheum		Children's Research Institute		R01HL164615	93.840	74,199	43,858	118,057
					University of Washington				184,305	-	184,305
					Uganda Heart Institute				268,190	-	268,190
		Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders Total							526,694	43,858	570,552
	HRSA	Autism Collaboration, Accountability, Research, Education, and Support	DBPNet ADHD Node CHOP SubN RE		Children's Hospital of Philadelphia		GRT-00001441	93.877	-	18,754	18,754
		Autism Collaboration, Accountability, Research, Education, and Support Total							-	18,754	18,754
	CDC	Chronic Diseases: Research, Control, and Prevention	Improving Pediatric Lupus Care		University of Utah		10064135-04-CCHMC	93.068	-	34,397	34,397
		Chronic Diseases: Research, Control, and Prevention Total							-	34,397	34,397
	Dept of Health and Human Serv Total								26,493,378	175,652,563	202,145,941
	Research and Development Cluster Total								26,735,398	180,231,739	206,967,137
Department of Transportation	NHTSA	State and Community Highway Safety	Occupant Protection Regional C		Ohio Department of Health		03130014BB0623	20.600	-	78,376	78,376
		State and Community Highway Safety Total							-	78,376	78,376
	Highway Safety Cluster Total								-	78,376	78,376
Department of Agriculture	USDA	Special Supplemental Nutrition Program for Women, Infants, and Children	Application Digital Accessibil	Food Research & Action Center	University of Cincinnati	238DC001M2003	238DC001M2003	10.557	89,046	27,498	116,544
Department of the Treasury	TREAS	Coronavirus State and Local Fiscal Recovery Funds	Enhancing Public Health Data S	Hamilton County Public Health	The Health Collaborative		COVID-19 Hamilton County ARPA	21.027	310,496	292,410	602,906
Department of the Treasury	TREAS	Coronavirus State and Local Fiscal Recovery Funds	ARPA funding coming from OHMHA	State of Ohio			COVID-19 OHMHAS	21.027	-	1,039,094	1,039,094
Department of the Treasury	TREAS	Coronavirus State and Local Fiscal Recovery Funds	SPR400528: FP_Warner MBH1_OHMHAS PRTF 2401290 SPR400328 09/01/2023 (version 0)	Ohio Dept. of Mental Health & Addiction			2401290 HB33-336648- ARPA	21.027	-	16,468	16,468
Dept of Health and Human Serv	CDC	Public Health Emergency Preparedness	Poison Center Bioterrorism Pre		Nationwide Children's Hospital		34225-A4	93.069	-	66,736	66,736
Dept of Health and Human Serv	CDC	Environmental Public Health and Emergency Response	ODH Asthma Home Assessment Pro		Ohio Department of Health		ODH_Newman	93.070	-	1,610	1,610

(Continued)

Children's Hospital Medical Center and Affiliates

Supplementary Schedule of Expenditure of Federal Awards (by Contract/Project)
For the Year Ended June 30, 2025

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Subrecipient Expenditure	Federal Expenditure	Total Expenditure
Dept of Health and Human Serv	CDC	Blood Disorder Program: Prevention, Surveillance and Research	Community Counts: Public Health Evaluation of Using the Connee	Hemophilia Foundation of Michigan		NU27DD000020	NU27DD000020	93.080	\$ -	\$ 23,809	\$ 23,809
Dept of Health and Human Serv	ACF	Personal Responsibility Education Program		Texas A & M		M2200564	90AP2702	93.092	-	286,225	286,225
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Region V East Comprehensive Care Network for Bleeding D	Hemophilia Foundation of Michigan		H30MC24047	H30MC24047	93.110	-	19,494	19,494
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Leadership Education in Neurod	University of Cincinnati		013719-0003	T73MC00032-30-W	93.110	-	552,810	552,810
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Cincinnati Developmental-Behav				T7749098	93.110	-	265,158	265,158
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	HRSA Central Region Thalassemi	Ann & Robert H Larie Children's Hospital		901639-CCHMC	U1AMC41738	93.110	-	7,966	7,966
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Center for Pediatric Everyday	University Hospital of Cleveland		DHHS HRSA-21-104 Regional	U1IMC43532	93.110	-	48,067	48,067
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Ohio Department of Health (ODH	Ohio State University		6 U7AMC337160101	U7AMC337160101	93.110	71,920	-	71,920
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Transition for Youth with Auti				H9E53186	93.110	7,022	184,230	198,667
					National Committee for Quality Assurance (NCQA)				7,415	-	-
Dept of Health and Human Serv	HRSA	Maternal and Child Health Federal Consolidated Programs	Newborn Screening Systems Qual	Association of Public Health Laboratoric		56300-600-158-22-24	UG8MC31893	93.110	5	39,083	39,083
Dept of Health and Human Serv	CDC	Disabilities Prevention	Improving the Health of People	Ohio State University		SPC - 1000005432	NU27DD000032	93.184	-	36,189	36,189
Dept of Health and Human Serv	HRSA	Poison Center Support and Enhancement Grant Program	Cincinnati Drug and Poison Inf				H4BHHS15468	93.253	-	349,075	349,075
Dept of Health and Human Serv	HRSA	Sickle Cell Treatment Demonstration Program	Sickle Treatment and Outcomes				U1E27863	93.365	8,446	842,202	1,284,396
Dept of Health and Human Serv	HRSA				Children's Hosp & Clinics of Minnesota				40,494	-	-
Dept of Health and Human Serv	HRSA				Five Rivers Health Centers				65,365	-	-
Dept of Health and Human Serv	HRSA				Indiana Hemophilia & Thrombosis Ctr, Inc				79,845	-	-
Dept of Health and Human Serv	HRSA				Medical College of Wisconsin				13,111	-	-
Dept of Health and Human Serv	HRSA				Sanford Research North				9,474	-	-
Dept of Health and Human Serv	HRSA				Univ of Michigan				55,998	-	-
Dept of Health and Human Serv	HRSA				University of Illinois at Chicago				135,953	-	-
Dept of Health and Human Serv	HRSA				University of Wisconsin System				33,508	-	-
Dept of Health and Human Serv	HRSA	Congressional Directives Discretionary	Cincinnati Children's 129Xe Hy				CE146670	93.493	-	67,625	67,625
Dept of Health and Human Serv	HRSA	Family to Family Health Information Centers	Ohio Family to Family Health I				H8428443	93.504	-	96,503	96,503
Dept of Health and Human Serv	ACL	Developmental Disabilities Projects of National Significance	National Center for Disability				90NCDE0001	93.631	12,500	320,049	496,774
Dept of Health and Human Serv	ACL				Autistic Self Advocacy Network Inc						
Dept of Health and Human Serv	ACL				Georgetown University				93.631	5,538	-
Dept of Health and Human Serv	ACL				Kennedy Krieger Institute, Inc.				93.631	155,548	-
Dept of Health and Human Serv	ACL				Morehouse School of Medicine Inc				93.631	3,139	-
Dept of Health and Human Serv	ACL	University Centers for Excellence in Developmental Disabilities Education, Research, and Service	University Centers for Excelle	University of Cincinnati		014723-00002	90DDUC0111	93.632	-	691,375	691,375
Dept of Health and Human Serv	ACL		Expanding the Public Health Wo	University of Cincinnati		014340-00002	90UCPH0030	93.632	-	10,775	10,775
Dept of Health and Human Serv	ASPR	National Bioterrorism Hospital Preparedness Program	Eastern Great Lakes Pediatric	University Hospital of Cleveland		U3REP190615	U3REP190615	93.889	-	167,647	167,647
Dept of Health and Human Serv	CDC	Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	OPQC: Addressing gaps and equi				1 NU58DP007264-01-00	93.946	45,003	224,774	408,540
Dept of Health and Human Serv	CDC				The Ohio State University- Central AR				60,630	-	-
Dept of Health and Human Serv	CDC				University of Iowa				78,133	-	-
Dept of Health and Human Serv	HRSA	Maternal and Child Health Services Block Grant to the States	Compassionate, Respectful, and	Ohio Department of Health			53702	93.994	-	299,139	299,139
Dept of Health and Human Serv	HRSA	Maternal and Child Health Services Block Grant to the States	Innovations to Advance Breastf	Ohio Department of Health		03130011BH0325		93.994	-	112,572	112,572
Dept of Health and Human Serv	SAMHSA	Opioid STR	SPR400009: McAllister - MHAS 5H79TI085753-02 SPR400009 09/30/2023 (version 0)	Ohio Dept. of Mental Health & Addiction		5H79TI085753-02	H79TI085753	93.788	-	79,255	79,255
Dept of Health and Human Serv	HRSA	Healthy Start Initiative	HRSA Cradle Cincinnati				H49MC27823	93.926	-	147,107	147,107
Dept of Health and Human Serv	SAMHSA	Block Grants for Prevention and Treatment of Substance Abuse	Substance Abuse Prevention and Treatment				ECS - MHRSB Hamilton County	93.959	-	257,394	257,394
Dept of Health and Human Serv	HRSA	Health Resources Services Administration & Administration for Children & Families	Maternal, Infant, and Early Childhood Home Visiting (MIECHV)	Ohio Department of Children and Youth			ECS - X1145269	93.870	143,637	5,087	148,724
Dept of Health and Human Serv	HRSA	Health Resources Services Administration & Administration for Children & Families	Maternal, Infant, and Early Childhood Home Visiting (MIECHV)	Ohio Department of Children and Youth			ECS - X110MC50322-01-00	93.870	332,538	7,164	339,702
Dept of Health and Human Serv	HRSA	Health Resources Services Administration & Administration for Children & Families	Maternal, Infant, and Early Childhood Home Visiting (MIECHV)	Northern Kentucky Independent Health District			ECS - X10MC50303-01-00	93.870	196,744	-	196,744
Dept of Health and Human Serv	HRSA				Brighton Center		ECS	93.870	361,926	-	361,926
Grand Total									\$ 29,058,832	\$ 186,894,705	\$ 215,953,537

(Concluded)

Children's Hospital Medical Center And Affiliates

Notes to Supplementary Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2025

1. SCOPE OF AUDIT

All federal grant operations of Children's Hospital Medical Center and Affiliates ("Cincinnati Children's", or the "Company") are included in the scope of Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)'s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the "Compliance Supplement"). The Department of Health and Human Services has been designated as Cincinnati Children's cognizant agency for the Single audit.

2. DE MINIMIS COST RATE

Cincinnati Children's did not elect to use the de minimis indirect cost rate as allowed under the Uniform Guidance.

3. SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

Basis of Presentation — The accompanying Supplemental Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant activity of Cincinnati Children's under programs of the federal government for the year ended June 30, 2025 and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Guidance. Because the Schedule presents only a selected portion of the operations of Cincinnati Children's, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children's.

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees of
Children's Hospital Medical Center and Affiliates
Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States ("*Government Auditing Standards*"), the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the Company's consolidated balance sheet as of June 30, 2025 and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements"), and have issued our report thereon dated September 30, 2025.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Company's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte + Touche LLP

September 30, 2025

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees
Children's Hospital Medical Center and Affiliates
Cincinnati, Ohio

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Children's Hospital Medical Center and Affiliates' (the "Company") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended June 30, 2025. The Company's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2025.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- obtain an understanding of the Company's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A *deficiency* in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the Company as of and for the year ended June 30, 2025, and have issued our report thereon dated September 30, 2025, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte + Touche LLP

March 11, 2026

Children’s Hospital Medical Center and Affiliates

Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2025

SECTION I. SUMMARY OF AUDITOR’S RESULTS

Financial Statements:

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP Unmodified

Internal control over financial reporting:

- Material weakness(es) identified? _____ Yes X No
- Significant deficiency(ies) identified? _____ Yes X None reported
- Noncompliance material to financial statements noted? _____ Yes X No

Federal Awards:

Internal control over major programs:

- Material weakness(es) identified? _____ Yes X No
- Significant deficiency(ies) identified? _____ Yes X None reported

Type of auditor’s report issued on compliance for major federal programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? _____ Yes X No

Identification of Major Programs:

ALN Number	Name of Federal Program or Cluster
Various	Research and Development Cluster (R&D)

Dollar threshold used to distinguish between Type A and Type B programs? \$ 3,000,000
Research and Development program tested as a single Type A program

Auditee qualified as low-risk auditee? _____ X Yes _____ No

Children's Hospital Medical Center and Affiliates

Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2025

SECTION II. FINANCIAL STATEMENT FINDINGS

None

SECTION III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None